

# U.S. ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE

USAMRICD-TR-00-10

The Effects of WR242511 in Rhesus Monkeys

Gary A. Rockwood Steven M. Duniho Crystal M. Briscoe Mark B. Gold Kevin R. Armstrong Ming L. Shih Anita V. Moran David W. Kahler Steven I. Baskin

May 2000

20001226 084

Approved for public release; distribution unlimited

U.S. Army Medical Research Institute of Chemical Defense Aberdeen Proving Ground, MD 21010-5400

#### **DISPOSITION INSTRUCTIONS:**

Destroy this report when no longer needed. Do not return to the originator.

#### **DISCLAIMERS:**

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

In conducting the research described in this report, the investigators adhered to the *Guide for the Care and Use of Laboratory Animals* by the Institute of Laboratory Animal Resources, National Research Council, in accordance with the stipulations mandated for an AAALAC accredited facility.

The use of trade names does not constitute an official endorsement or approval of the use of such commercial hardware or software. This document may not be cited for purposes of advertisement.

#### REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

	•		
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE May 2000	3. REPORT TYPE AN Technical, May 19	
4. TITLE AND SUBTITLE The Effects of WR24511 in Rhesus M	Monkeys		5. FUNDING NUMBERS 30162384ATC2 62384A
6. AUTHOR(S) Rockwood, GA, Duniho, SM, Brisco Moran, AV, Kahler, DW, and Baskin		rong, KR, Shih, ML,	·
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research Institute of Chemical Defense ATTN: MCMR-UV-DA 3100 Ricketts Point Road Aberdeen Proving Ground, MD 21010-5400			8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING/MONITORING AGENCY Commander U.S. Army Medical Research Institut	.,	)	10. SPONSORING/MONITORING AGENCY REPORT NUMBER
ATTN: MCMR-UV-RC 3100 Ricketts Point Road Aberdeen Proving Ground, MD 210	10-5400		USAMRICD-TR-00-10
11. SUPPLEMENTARY NOTES			

# 12a. DISTRIBUTION/AVAILABILITY STATEMENT

12b. DISTRIBUTION CODE

Approved for public release; distribution unlimited.

#### 13. ABSTRACT (Maximum 200 words)

Many substances that form methemoglobin (MHb) counter cyanide (CN) toxicity. Although MHb formers can be applied as treatments for CN poisoning, it was reasoned that a long-acting MHb former could serve as a CN pretreatment. An 8aminoquinoline drug, WR242511, was characterized as a long-lasting MHb former, producing sufficient MHb to protect against 2 X LD<sub>50</sub> of CN. Transition for development of WR242511 was based on data from rodents and beagle dogs collected elsewhere. Advanced development testing of WR242511 at USAMRICD was conducted in the rhesus monkey. WR242511 was administered intravenously (IV) to two female and four male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg, with the objective of producing protective levels of MHb. A single drug-naïve male received WR242511 PER OS at 7.0 mg/kg. Although WR242511 at these doses produced up to 22.6% MHb in beagle dogs in earlier studies conducted elsewhere, it produced little MHb (mean < 2.0%) in the rhesus monkey. Transient hemoglobinuria was noted approximately 60 min post-injection. Two lethalities occurred following the 7.0 mg/kg dose (one IV and one PER OS). Histopathology revealed multiple organ toxicity, with greater severity in the PER OS-treated animal. These findings do not support the continued development of WR242511 as a CN pretreatment.

14. SUBJECT TERMS cyanide, toxicity, WR242511, rhesus monkeys, pathology, methemoglobin			15. NUMBER OF PAGES 76
			16. PRICE CODE
S17. ECURITY CLASSIFICATION OF REPORT UNCLASSIFIED	18. SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED	19. SECURITY CLASSIFICATION OF ABSTRACT UNCLASSIFIED	20. LIMITATION OF ABSTRACT UNLIMITED

### **Table of Contents**

I.	Introduction and Background	1
II.	Experimental segments in protocol 759	3
	II.1. Segment A	4
	II.2. Segment B	5
	II.3. Discussion	17
III.	References	21
Lis	st of Appendicies	
A.	List of Participants	25
B.	Timeline	29
C.	Test Articles	. 33
D.	Animal Histories	37
E.	Hematologic Data 41	
F.	Hematologic Data and Blood Chemistry Data (WR242511)	49
G.	Original Necropsy Reports	73
H.	Purity Tests	81
I.	Pyrogen Testing Results	85

#### I. Introduction and Background

Methemoglobin (MHb) formation is an effective strategy to counter cyanide (CN) toxicity (Chen and Rose, 1952; Baskin and Fricke, 1992; Rockwood et al., 1999). An 8-aminoquinoline, 8-[(4-amino-l-methylbutyl)amino]-5-(l-hexyloxy)-6-methoxy-4-methyl quinoline (DL-tartrate), hereafter referred to as WR242511 (see Figure 1), was initially targeted for its potent anti-malarial properties. However, it was discontinued as a candidate anti-malarial compound due to a significant "side-effect," viz., MHb formation. Subsequently, when its MHb-forming capacity was systematically characterized, WR242511 emerged as a leading anti-CN compound (Transition Information Paper, 1994). In dogs, this compound was shown to have a long half-life and yield stable steady-state MHb levels (Marino et al., 1994). WR242511 was recommended for transition as a CN pretreatment to Milestone 1 in December 1994 (Transition Information Paper, 1994). This transition to Milestone 1 occurred in March 1995.

This report describes an advanced development project designed to evaluate the safety and behavioral efficacy of WR242511 for use as a pretreatment against CN poisoning. Rhesus monkeys served as subjects. Research was conducted at the US Army Medical Research Institute of Chemical Defense (USAMRICD), APG-EA, MD, under USAMRICD animal use protocol 1-05-98-000-A-759 (hereafter referred to as protocol 759) (Rockwood, 1998). See Appendices A and B for a list of project participants and for a complete timeline of events relevant to this report, respectively.

Various species, such as rats, mice, sheep and dogs have been used in the study of MHb formers and MHb formation, with the beagle dog being used particularly often (Bright and Marrs, 1986; Marino et al., 1994; Marrs and Bright, 1986). Beagle dogs have been used for the study of numerous classes of MHb formers, including 8-aminoquinolines, such as WR242511 (Marino et al., 1994; Levine et al., 1996), as well as aminophenones (Bright et al., 1987), and aminophenols (Bright and Marrs, 1982).

A significant portion of protocol 759 was designed to evaluate the effects of WR242511 on cognitive status in rhesus monkeys utilizing an established nonhuman primate version of the Serial Probe Recognition (SPR) task (Castro, 1995, 1997; Castro et al., 1992, 1994). The rhesus monkey was designated as the test species for two principal reasons. First, use of this species would allow for consistency across our advanced development database. Second, there was compelling evidence demonstrating the appropriateness of using rhesus monkeys in the study of 8-aminoquinolines and related compounds. For example, it is noteworthy that the rhesus monkey was the model of choice for the extensive US Army post-WWII-era evaluation of novel anti-malarials, including numerous 4- as well as 8-aminoquinolines (excluding WR242511, which had not yet been synthesized) (Wiselogle, 1946). Schmidt and colleagues demonstrated that following exposure to a large number of potential anti-malarial compounds, the rhesus monkey exhibited similar toxicological as well as neurological sequelae as reported in humans (Blanchard and Schmidt, 1946; Schmidt, 1983; Schmidt and Schmidt, 1949; Schmidt et al., 1977).

$$CH_2(CH_2)_4CH_3$$
 $O$ 
 $CH_3$ 
 $H_3CO$ 
 $N$ 
 $HN$ 
 $CH(CH_2)_3NH_2$ 
 $CH_3$ 

Figure 1. Structure of test compound WR242511.

#### II. Experimental segments in protocol 759

Original experimental segments for protocol 759 are presented in Table 1. Segment A (calibration) was designed principally as a proof-of-concept segment, to verify available information on rhesus monkey reactivity and sensitivity to MHb formers (Wiselogle, 1946; Moe et al., 1949; Martin et al., 1995) since only scant relevant information was available. [In addition, Segment A allowed for the generation of calibration equations for a non-invasive MHb monitor prototype. Use of this non-invasive MHb monitor prototype had no impact on the outcome of the research described herein and was only employed during the calibration segment of this protocol. It was not used in conjunction with WR242511. Therefore, no further discussion or description of this non-invasive MHb monitor prototype is included in this report.] The prototypic MHb former sodium nitrite (NaNO2) was utilized to induce MHb during Segment A. This compound has been used experimentally as well as clinically since the 1930s as an efficacious treatment for CN toxicity and is one of the components in the DoD anti-CN kit. Following Segment A. the intention was to determine the dose range of WR242511 that yielded 5-7% MHb (Segment B). The results of Segment A are included in this report; however, the focus is on the results of Segment B. The remaining three segments depicted in Table 1 (Segments C-E) were not conducted due to severe reactions to WR242511 in rhesus monkeys, as described below. Test articles described in this report are presented in Appendix C.

Table 1. Original experimental segments in protocol 759 (Rockwood, 1998).

Segment	Procedure
	- Induce MHb in rhesus monkeys using sodium nitrite (n=6)
A (Calibration)	- Calibrate the Datex-Ohmeda non-invasive MHb monitor in non-SPR-trained animals
	- Validate the results using arterial blood samples analyzed using the OSM3 Hemoximeter
	- Determine dose of WR242511 that produces ~5-7% MHb
B	- Examine time-course for MHb changes
(Preliminary dose-ranging)	- Use animals from Segment A (n=6)
С	<ul> <li>Pretreat a subset of animals used in Segments A and B (n=2) with dose of WR242511 determined to produce ~5-7% MHb in each animal</li> </ul>
(Preliminary challenge)	<ul> <li>Challenge with 2 X MLD sodium cyanide (CN), and determine protective effect of MHb against CN toxicity</li> </ul>
D	- Ascertain the individual dose of WR242511 for each SPR-trained
(Phase I testing -Drug	animal (n=10), to produce a MHb level of ~5-7%
Safety)	- Evaluate SPR performance (vs baseline) under this level of MHb
E	- Administer 2 X MLD challenge of CN to same animals used in
(Phase II testing – Segment D (n=10), after pretreatment with WR242511	
Behavioral Efficacy)	- Evaluate recovery and time-course of return to SPR baseline levels

#### II.1. Segment A

A preliminary portion of Segment A has been presented elsewhere (Rockwood et al., 1999).

#### II.1.a. Methodology

#### II.1.a.1. Animals

Six rhesus monkeys (*Macaca mulatta*) served as subjects (two females and four males). All animals were healthy and had no history of chronic illness, severe injury or exposure to MHb-forming compounds. Animal histories are presented in Appendix D. Initial average animal weights were 5.6 kg and 9.7 kg, for females and males, respectively. The following animals were tested in this segment:

P3C (Sheba)	Female
B055 (Nancy)	Female
7AS (Astin)	Male
JW0 (Joe)	Male
F942 (Kong)	Male
16999 (Byron)	Male

#### II.1.a.2. Procedure

All animals were tested individually. Each animal was anesthetized with 3.0 mg/kg (administered intramuscularly) tiletamine HCl/zolazepam HCl (Telazol®) and maintained on a surgical plane with isoflurane (0.5-2.0% in oxygen). An arterial catheter was placed centrally, allowing for serial blood sampling as required for hematologic evaluation.

NaNO<sub>2</sub> (prepared in 0.9% saline on the day of testing; 1.0 ml/kg) was administered intravenously (iv) in increments until approximately 15.0 % MHb was achieved, or until a maximum of approximately 20 mg/kg had been administered. Animals received a total of six or seven infusions of NaNO<sub>2</sub>, with an average of 26.5 min between each infusion. Mean time between NaNO<sub>2</sub> infusion and blood sampling was 17.4 min (range: 15.8-19.8 min). Hematologic information, including MHb, as well as total hemoglobin (tHb), oxyhemoglobin (HbO<sub>2</sub>), reduced hemoglobin (RHb), oxygen content (O<sub>2</sub>Ct), sulfhemoglobin (SHb) were analyzed using OSM3 Hemoximeter technology (Radiometer America).

#### II.1.b. Results

Animals received a cumulative dose of 16.0-20.0 mg/kg of NaNO<sub>2</sub>, across an average of 163 min. Baseline MHb levels were all <1.0%, with a mean of 0.45%. Maximum MHb levels observed ranged from 8.6-15.5% (Table 2). Not surprisingly, serial NaNO<sub>2</sub> injections corresponded closely with increasing MHb levels (Pearson's r values > 0.95). In addition, with increasing levels of NaNO<sub>2</sub>, there were decreases in tHb, HBO<sub>2</sub>, and

O<sub>2</sub>Ct, as well as an increase in RHb. No changes in SHb were observed. See Appendix E for additional details pertaining to these results.

Table 2. Segment A MHb summary.

Animal	Initial weight (kg)	Cumulative NaNO <sub>2</sub> (mg/kg)	Maximum % MHb
16999 (Byron)	10.6	19.0	15.2
B055 (Nancy)	7.2	16.0	15.5
7AS (Astin)	9.2	19.2	10.5
JW0 (Joe)	8.8	19.4	9.6
F942 (Kong)	10.0	20.0	10.0
P3C (Sheba)	3.9	19.6	8.6

#### II.2. Segment B

#### II.2.a. Methodology

#### II.2.a.1. Animals

All six animals from Segment A also served as subjects in Segment B. An additional healthy male rhesus monkey (6VY, Adams, 12.6 kg) was also used in this segment. See Appendix A for history on 6VY. The following animals were tested in this segment:

P3C (Sheba)	Female
B055 (Nancy)	Female
7AS (Astin)	Male
JW0 (Joe)	Male
F942 (Kong)	Male
16999 (Byron)	Male
6VY (Adams)	Male

#### II.2.a.2. Procedures

All procedures were reviewed and approved by the Institute Animal Care and Use Committee. Animals were restraint-chair trained by USAMRICD personnel prior to testing and remained in the chair for 1 hr postinjection before being returned to their home cage. On the day of testing, animals were tested individually. WR242511 was initially prepared in PEG200 in a concentration of 7.0 mg/ml. Subsequently, WR242511 was prepared in Multisol, in a concentration of 14.0 mg/ml. Injections were administered iv, in a volume of 0.5 ml/kg, yielding doses of 3.5 and 7.0 mg/kg, using PEG200 and Multisol, respectively. Injections were administered across 2-3 min. Doses were selected based on experiments in beagle dogs, as summarized in the Transition Information Paper (1994). The iv route was selected for ease of administration, since

previous reports in beagle dogs demonstrated similar patterns of MHb formation by iv and oral routes of administration (Noker, 1994; Transition Information Paper, 1994).

Drug solutions were prepared fresh on the day prior to or on the day of use. When a solution was prepared on the day prior to use, the solution was kept in a refrigerator until the following morning. Solutions were always maintained in an amber glass vial. To facilitate solution preparation, sonication and heat were applied. In a conversation with personnel at Ash Stevens Inc. (the laboratory that synthesized WR242511 in ~1990) about solubility difficulty, it was indicated that the compound has a maximum quantitative solubility of 2.5 mg/ml in water. The solubility characteristics of this compound in PEG200, however, were unknown. However, there was little concern that sonication, heat or manually crushing the compound, to facilitate solution preparation, would adversely affect compound stability (Blumbergs, August 1998, personal communication).

During the day of WR242511 injection, venous blood samples were obtained prior to injection, and at 1, 6, 12, and 24 hr postinjection. Subsequent blood sampling occurred daily for as long as 11 days postinjection. Samples were analyzed using the OSM3 Hemoximeter. Full blood chemistry analyses were performed as needed by personnel in the Comparative Pathology Branch at USAMRICD. Urine was collected in a catch tray positioned below the restraint chair.

#### II.2.b. Results and Procedure Modifications

As depicted in Table 3, all animals, except one, received an iv injection of WR242511 at 3.5 mg/kg. During injection of the remaining animal, the catheter clogged, and the injection could not be completed. Therefore, this animal received 3.14 mg/kg instead of 3.5 mg/kg. Baseline levels of MHb were all <1.0%, with a mean of 0.62%. Additional hematological parameters, as well as blood chemistry, are presented in Appendix F.

Table 3. Segment B MHb summary following iv administration of WR242511 (3.5 mg/kg).

Animal	WR242511 Dose (mg/kg)	Maximum % MHb observed (time)
700 (01.1.)		
PC3 (Sheba)	3.5	0.9 (72 hr postinjection)
7AS (Astin)	3.5	1.5 (96 hr postinjection)
B055 (Nancy)	3.5	3.9 (48 hr postinjection)
JW0 (Joe)	3.14*	1.1 (72 hr postinjection)
F942 (Kong)	3.5	1.0 (72 hr postinjection)
16999 (Byron)	3.5	1.0 (48 hr postinjection)

<sup>\*(</sup>clogged catheter)

At approximately 60 min postinjection, dark (reddish/brown) urine was observed (hemoglobinuria). The first incidence was noticed after the animal was returned to its home cage. It was not immediately clear whether the fluid was darkened urine or blood from an injury. The animal was immediately placed back into the restraint chair for examination. The veterinarian determined that there was no outward injury or irritation, and the animal was returned to its home cage. Subsequent animals also displayed hemoglobinuria at approximately the same point postinjection (60 min). The hemoglobinuria was temporary, observed during the first urination postinjection (~60 min), but not at later times. It remained unclear whether the hemoglobinuria resulted from the drug, the solvent, or perhaps from undetected irritation due to the length of time the animals remained in the restraint chair (~65 min). It is noteworthy that for several days after WR242511 injection, the blood samples drawn for analysis appeared viscous, and brown-tinged. These observed changes were more pronounced at the higher dose (see below).

To examine possible diluent and/or chair effects, a single subject (7AS) was given an iv injection of PEG200 alone (0.5 ml/kg). The procedure was conducted 26 days after this same animal received 3.5 mg/kg WR242511. Following PEG200 alone, this animal displayed hemoglobinuria at approximately 60 min postinjection. A second animal (F942) was placed in the restraint chair for ~60 min. No darkened urine was produced. A potential alternative solvent, Multisol, was identified. Multisol (48.5% water, 40% propylene glycol, 10% ethanol and 1.5% benzyl alcohol) is used as a solvent for preparing injectable drug solutions at USAMRICD and is the diluent for injectable diazepam. A single subject (16999) given an iv injection of Multisol (0.5 ml/kg) displayed no hemoglobinuria. Therefore, Multisol was selected as the new solvent for the preparation of WR242511. In addition to changing the solvent, the dose was increased from 3.5 mg/kg to 7.0 mg/kg, because very little MHb was produced at the lower dose. These changes were approved by the WR242511 Steering Committee.

Two subjects (P3C, female and JW0, male) were each administered WR242511 (7.0 mg/kg, in Multisol). Hemoglobinuria was observed in each animal. As presented in Table 4, very little MHb was produced, and JW0 died at ~36 hr postinjection. The attending veterinarian provided supportive treatment, and P3C survived. A full necropsy was performed on JW0. These results are presented in a subsequent section of this report. Additional hematological parameters, as well as blood chemistry results, are presented in Appendix F.

Table 4. Summary of initial iv administration of 7.0 mg/kg WR242511 in rhesus monkeys.

Animal	Maximum % MHb observed (time)	Outcome
P3C	1.3 (96 hr postinjection)	Sick, shock, survived (with intervention by veterinarian)
JW0	1.0 (6 hr postinjection)	Died ~36 hr postinjection

Several potential reasons for the outcome at 7.0 mg/kg were addressed by the WR242511 Steering Committee, and two additional tests were recommended. First, it was suggested that WR242511 be administered iv over an extended time (60 min). Second, it was suggested WR242511 be administered via the oral route. These additional studies are described below.

In a single male rhesus (F942), WR242511 (7.0 mg/kg, in Multisol) was administered iv, across 1 hr. For this iv injection, volume was 1.0 ml/kg. In this slow-infusion test, the animal was anesthetized (Telazol®), and WR242511 was administered iv using an infusion pump. A catheter was inserted to allow for urine sampling. No elevated MHb was observed, but hemoglobinuria was very apparent. Starting at 5 min postinjection, the urine became increasingly darker, and by 60 min postinjection, the urine sample was a very dark reddish brown with apparent sediment. Subsequent urine samples were clear. This animal did not appear sick and survived with no apparent ill effects. Additional hematological parameters, as well as blood chemistry results, are presented in Appendix F.

The final test in a rhesus monkey with WR242511 was to administer the drug orally. In this test, a WR242511-naïve male rhesus (6VY) was lightly anesthetized, and administered WR242511 (7.0 mg/kg, prepared in Multisol, in a volume of 2.0 ml/kg) via gastric intubation. No darkened urine was observed. This animal showed no appreciable MHb elevation (baseline: 0.5%, maximum MHb observed postinjection: 0.9%). Vomiting was observed at 24, 36 and 48 hr postinjection. The attending veterinarian monitored the animal, and noted nothing remarkable. The animal appeared alert, and aside from the vomiting, healthy. By 96 hr postinjection, the animal took a turn for the worse, and the attending veterinarian administered fluids. However, the animal died shortly thereafter (approximately 2 hr). A complete necropsy was performed (see below). This unexpected death was followed by solvent/procedure control test. Multisol alone was administered orally, under conditions identical to those present during the WR242511 oral exposure. No ill effects were noted in 16999 following Multisol alone. Additional hematological parameters, as well as blood chemistry results, are presented in Appendix F.

Table 5. Summary of effects of slow-infusion iv or oral administration of 7.0 mg/kg WR242511, or solvent control, in rhesus monkeys.

Animal	Route	Treatment	Dose	Outcome
F942	iv (slow)	WR242511	7.0 mg/kg	hemoglobinuria
6VY	per os	WR242511	7.0 mg/kg	hemoglobinuria,
				vomiting, died
16999	per os	Multisol	-	no ill effects

#### II.2.c. Pathology Reports

#### II.2.c.1. Clinical History

An adult, male rhesus monkey (JW0) was given two iv injections of WR242511 on two different occasions using two different solvents, PEG200 and Multisol (see Appendix B). Both administrations resulted in dark urine within one hr, and urinalysis confirmed the presence of hemoglobinuria. On day 1 after WR242511 (7.0 mg/kg) exposure, it was noted that the animal had vomited and had loose stools. Also, the animal appeared, lethargic, and was not eating. The animal was given supportive therapy, but died on day 2 postexposure. A complete necropsy was performed on 01 October 98.

A second adult, male rhesus monkey (6VY) received an oral treatment of WR242511 (7.0 mg/kg, prepared in Multisol, administered in volume of 2 ml/kg) via oral intubation. The animal vomited several times on days 2 and 3 postexposure. The animal was observed on the bottom of its cage on day 4 postexposure. Although supportive therapy was administered, the animal died several hr later. A complete necropsy was performed on 26 April 99. Urinalysis from a sample collected during postmortem examination revealed elevated protein and the presence of occult blood.

#### II.2.c.2. Necropsy results

Animal JW0 had no significant postmortem gross lesions. The carcass was in good flesh.

Animal 6VY was in good nutritional condition with ample subcutaneous and cavitary fat. There was a small amount of regurgitated food in the larynx. There were multiple organ ecchymoses and hemorrhages involving the epicardial surface of the heart, pericardium, internal thorax, and pancreas. The liver was diffusely dark red with a light-colored reticulated pattern that accentuates hepatic lobules (see Figure 3).

Copies of the original necropsy reports for animals JW0 and 6VY are presented in Appendix G.

#### II.2.c.3. Microscopic results

#### A. Animal JW0:

The lungs were diffusely and severely expanded by edema and fibrinous exudate (see Figure 2). Multifocally, several pulmonary arteries contained fibrin thrombi (see Figure 2). The liver exhibited diffuse, moderate hepatocellular degeneration, and congestion. There was mild, multifocal renal tubular epithelial degeneration and congestion. There was multifocal, mild, subacute myocarditis with a focal area of hemorrhage.

#### B. Animal 6VY:

The hepatic architecture was completely disrupted by sublobular necrosis and diffuse hemorrhage with moderate to severe periportal hepatocellular degeneration (see Figure 4). There was moderate to severe degeneration and necrosis of tubular renal epithelium, and, multifocally, tubules contain cellular, granular or hemoglobin casts (see Figure 5). The presence of intratubular hemoglobin was confirmed with special stains. There was diffuse, acute necrosis of the adrenal zona reticularis. There was mild, acute hemorrhage in the subendocardial and myocardial regions of the heart, accompanied by scattered myocardial degeneration. There was also multifocal, mild acute hemorrhage present in the periductular regions of the pancreas, meninges, pericardium, periesophageal fibroadipose tissue, and thymus. The hemorrhage in the pericardium was accompanied, multifocally, by intrarteriolar fibrin thrombi.

#### II.2.c.4. Comments

The histopathologic results strongly suggest that the lesions in the liver and kidney of both animals were the result of acute toxicity, although of varying degrees. The presence of hemorrhage in multiple organs from animal 6VY is compatible with a generalized coagulation disorder most likely secondary to severe liver dysfunction. Necrosis of the zona reticularis in the adrenal gland of animal 6VY is also consistent with an acute toxic insult. The presence of hemoglobin in urine and renal tubules indicates intravascular red blood cell damage (hemolysis). The exact mechanism of hemolysis is unknown. The pulmonary lesions in animal JWO reflect severe extravascular leakage of proteinaceous fluid and fibrin thrombosis. In light of the other lesions in these two animals, it is speculated that this too may be the result of a toxic effect on the pulmonary microvasculature. Although the acute myocardial hemorrhage appears to be related to the toxic events in both animals, the myocarditis is probably an older lesion. The different routes of administration (oral vs. intravenous) most likely explain the difference in target organs and severity of lesions in these two animals. The exact mechanism of toxic injury, whether an effect of the compound itself and/or a biotransformed metabolite, is uncertain.




Figure 2. Lung with pulmonary edema and fibrin thrombus




Figure 3. Liver with diffuse congestion and reticular pattern.




Figure 4. Liver with submassive necrosis and hemorrhage.




Figure 5. Kidney with degenerative and necrotic tubules.

#### II.2.d. Chemical Analysis

As a means of determining whether or not the observed effects on rhesus monkeys were due to a degraded or tainted sample, we provided several sample WR242511 solutions, as well as samples of the solvents, to the laboratory of Dr. Ming Shih, USAMRICD. She and her technician, Mr. J. Richard Smith performed mass spectrometry analyses on these samples. The results are provided below. In addition, to examine the possibility of pyrogen contamination, we sent sample WR242511 solutions, as well as samples of the solvents to the Celsis Laboratory Group. These results are also presented below.

#### II.2.d.1. Mass Spectrometry: Experimental

Solutions of WR242511 (ICD#1359) in Multisol were introduced to a mass spectrometer via a liquid stream consisting of a mixture of acetonitrile and water (90/10, v/v) delivered isocratically at 0.4 mL min<sup>-1</sup> using a Hewlett Packard G1312A binary pump. The liquid stream was passed through a Hewlett Packard G1322A vacuum degasser prior to pump delivery. Samples were injected using flow injection analysis (FIA) with a Hewlett Packard G1313A automatic liquid sampler. The injection volume was 5 μL. Following FIA, the liquid stream was passed through a Hewlett Packard G1315A diode array detector (DAD) and then directed into a Hewlett Packard G1946A quadrupole mass spectrometer via an atmospheric pressure electrospray ionization (ESI) interface. UV absorbance was measured at 210 nm using a bandwidth of 4 nm with no reference wavelength used. The following MS conditions were used: positive ion full scan from *m/z* 70 to 600 resulting in a cycling time of 0.4 sec per cycle, fragmentor at 80 V, and capillary voltage at 4000 V. The drying gas was nitrogen introduced at a flow rate of 10 L min<sup>-1</sup> and kept at 350 °C. Nitrogen was also used as the nebulization gas and maintained at a pressure of 40 psi.

#### II.2.d.2. Mass Spectrometry: Results

Electrospray ionization/mass spectrometry generally produces a [M+H]<sup>+</sup> protonated form of the molecular ion. The molecular weight of WR242511 without the DL tartarate salt is 373. The [M+H]<sup>+</sup> ion for WR242511 was readily observed at m/z 374 (see Figure 6). Small fragment ions of the parent compound were also observed at m/z 357 and 289. Their identification as fragment ions was confirmed by increasing the fragmentor voltage to induce greater fragmentation of the parent compound with a corresponding loss of the molecular ion. The solution was left out overnight (approximately 16 hr) at room temperature and exposed to air. No noticeable change in the mass spectrum was observed (see Figure 7). A fresh solution of WR242511 in Multisol was prepared and analyzed within 24 hr. The [M+H]<sup>+</sup> ion for WR242511 was once again readily observed at m/z 374 (see Figure 8). This solution was more dilute than the solution analyzed in Figure 5. As a result, ions from the Multisol solution were observed (see Figure 9). Analysis of the Multisol solution without WR242511 confirmed that the additional ions resulted from the Multisol. For additional information, see Appendix H.





Figure 6 Mass spectrum of WR242511 (ICD # 1359) in Multisol (13.5 µg/ml<sup>-1</sup>); prepared on 21 April 1999 and analyzed on 17 May 1999.







Figure 8. Mass spectrum of WR242511 (ICD # 1359) in Multisol (4.0 µg/ml<sup>-1</sup>); prepared on 17 May 1999 and analyzed on 18 May 1999.

Figure 9. Mass spectrum of Multisol solution; prepared on 21 April 1999 and analyzed on 18 May 1999.



#### II.2.e. Pyrogen Testing

The results from these tests are presented in Appendix I. The samples appeared pyrogen-free, although very low pyrogen levels, below the threshold of detection, cannot be ruled out. It appears unlikely, however, that pyrogen contamination (in the drug or solvents) can explain the WR242511 results in the rhesus monkey, since similar types of toxicity have been seen in other species.

#### II.3. Discussion

Rhesus monkeys showed a typical elevation in blood MHb levels in response to iv injections of the prototypic MHb former NaNO<sub>2</sub> (Segment A). However, the experimental compound, WR242511, a potent MHb former in dogs, produce little or no elevation of MHb levels in rhesus monkeys (Segment B). Furthermore, toxicity was observed in the rhesus monkey exposed to WR242511, ranging from hemoglobinuria to liver damage, with death resulting in the most severely affected animals. Oxyhemoglobin levels also decreased following WR242511; cyanosis, however, was not apparent. Although sample sizes were small, we explored several possible reasons for these findings in the rhesus monkey exposed to WR242511.

#### 1) SOLVENT

We examined the original solvent, PEG200. When WR242511 (3.5 mg/kg, iv) was first administered, with PEG200 as the solvent, hemoglobinuria was observed. Because hemoglobinuria was also observed in a single rhesus that received PEG200 alone, this solvent was replaced with Multisol. Multisol, alone, did not result in hemoglobinuria. However, when WR242511, prepared with Multisol, was administered, hemoglobinuria resulted. It is possible that the hemoglobinuria that was observed following PEG200 alone was, in fact, not due to the solvent. Rather, that particular animal had received 3.5 mg/kg WR242511 approximately 26 days prior to the PEG200 alone exposure. It is possible that WR242511 from the original exposure remained sequestered in the animal. When PEG200 alone was administered to this animal 26 days later, the sequestered drug was disturbed and produced the observed hemoglobinuria.

#### 2) CHAIRING PROCEDURE

Chairing a rhesus monkey for 1 hr (or slightly longer) was also examined as a possible explanation for the hemoglobinuria. This, however, was ruled out.

#### 3) RATE OF IV INJECTION

WR242511 was initially administered iv across 2-3 min. To address concerns about the total injection time, a slow-infusion (1 hr) test was performed. The animal survived, but did exhibit hemoglobinuria.

#### 4) ROUTE OF ADMINISTRATION

WR242511 was initially administered iv in rhesus monkeys. All animals exhibited hemoglobinuria. One animal, which received 7.0 mg/kg, died, and a second animal which received this dose became ill, but recovered. When a single rhesus monkey was

orally dosed with 7.0 mg/kg WR242511, the animal died. It is noteworthy that in the beagle dog treated with WR242511 at the same doses used in the present study, the iv and per os routes of administration yielded similar patterns of methemoglobinemia (Noker, 1994).

#### 5) DOSE

The doses used in this study are consistent with doses used previously in the beagle dog to produce MHb levels within the target range (Noker, 1994).

#### 6) DRUG LOT AND CHEMICAL PURITY

The bottle number of WR242511 used in the present study with rhesus monkey is identical to that used by Noker (1994). Furthermore, to date, all analyses suggest that the test article was analytically pure and pyrogen-free.

#### 7) SPECIES

Based on information currently available, the rhesus monkey appears to have been appropriate for this study. The rhesus monkey showed consistent MHb elevation following exposure to NaNO<sub>2</sub> (Segment A). Older data show that several 8-aminoquinolines produced elevated MHb in rhesus monkeys (Blanchard and Schmidt, 1946; Moe et al., 1949). Furthermore, levels of enzymes important for species-sensitivity and responsiveness to MHb-forming drugs, such as glucose-6-phosphate dehydrogenase and methemoglobin reductase are similar in the rhesus monkey and in humans (Eng, 1962; Rockwood et al., 2000).

The toxicity observed in the rhesus monkey following WR242511 does not appear to be unique to this species. Levine et al. (1996) reported a pattern of toxicity in rats and dogs following oral WR242511. However, three pieces of evidence in the beagle dog demonstrate toxicity particularly similar to that described in the rhesus monkeys.

- (1) In the final report by Dr. Patricia Noker entitled "Single dose iv and oral pharmacokinetics, bioavailability and metabolism study of WR242511 in dogs" (1994), hematuria was noted for the first day after drug administration in all dogs that received iv 7.0 mg/kg WR242511 (prepared in PEG200).
- (2) In a study summarized in a US Army-funded final report entitled, "Effects of methemoglobin versus potassium cyanide intoxication," by Dr. William D. Johnson (1987), one of two dogs died after receiving oral (gelatin capsules) WR242511 at 7.024 mg/kg once daily for four consecutive days. Unfortunately, a necropsy was not performed, and cause of death was not determined. It is unlikely, however, that methemoglobinemia precipitated the death, since MHb levels had started to decline (i.e., MHb levels were 32% and 29% three and two days prior to death, respectively). At specific times following the last day of drug administration, both animals receiving the multiple dosing regimen of WR242511 described above exhibited decreased activity (days 2-9), anorexia (days 2-9), diarrhea (days 3-4), and no stools (days 5-9). Furthermore, in the animal that died, considerable increases were observed in alanine aminotransferase (ALT),

aspartate aminotransferase (AST) and alkaline phosphatase (SAP) at 72 hr, 5 and 12 days after WR242511 administration, compared with baseline. These likely correspond to "hepatic cellular degeneration, skeletal and cardiac degeneration and/or obstructive icterus in dogs for ALT, AST and/or SAP, respectively. These increases were most likely a direct result of WR 242,511 administration" (p. 33). Other dogs reported in this study received a single oral dose of WR242511 at 7.024 or 14.048 mg/kg (two dogs per dose). One subject that received 14.048 mg/kg showed similar changes in ALT, AST and SAP at 72 hr after drug administration. No other significant changes were noted in these other animals, aside from time-dependent increases in MHb levels. Johnson (1987) concluded that, "Although WR242511 is a potent methemoglobin inducer, its associated toxicity, at least at the dose levels used in this study, would preclude its use as a cyanide antidote." (p. 42)

(3) In an open literature paper entitled, "Pharmacokinetics and kinetic-dynamic modeling of an 8-aminoquinoline candidate anticyanide and antimalarial drug (WR242511)," Marino et al. (1994) stated that all (beagle) dogs that received either iv (3.5 or 7.0 mg/kg, prepared in PEG200) or oral (7.0 mg/kg, gelatin capsules) WR242511 showed hemolysis, which cleared within 48 hr; however, gross hemoglobinuria was not observed. In addition, one animal vomited after receiving an oral dose of 7.0 mg/kg.

To date, data suggest that WR242511 is toxic across species and route of administration. Unless the anti-CN characteristics of this compound can be successfully dissociated from those that produce undesirable toxicity, WR242511 should not be pursued as a pretreatment for CN poisoning.

#### III. References

- Baskin, S.I. and Fricke, R.F. (1992). The pharmacology of p-aminopropiophenone in the detoxification of cyanide. Drug Rev, 10: 358-375.
- Blanchard, K.C. and Schmidt, L.H. (1946). Chemical series of potential interest. In: A survey of antimalarial drugs (F.Y. Wiselogle, ed.), J.W. Edwards: Michigan, v.1, pp. 73-175.
- Bright, J.E. and Marrs, T.C. (1982). A model for the induction of moderate levels of methaemoglobinemia in man using 4-dimethylaminophenol. Arch Toxicol, 50: 57-64.
- Bright, J.E. and Marrs, T.C. (1986). Kinetics of methaemoglobin production (2). Kinetics of the cyanide antidote p-aminopropiophenone during oral administration. Human Toxicol, 5: 303-307.
- Bright, J.E., Woodman, A.C., Marrs, T.C. and Wood, S.G. (1987). Sex differences in the production of methemoglobinemia by 4-aminopropiophenone. Xenobiotica, 17: 79-83.
- Castro, C.A. (1995). Primacy and recency effects in Rhesus monkeys (Macaca mulatta) using a serial probe recognition task: I. Effects of diazepam. Psychopharm, 119: 421-427.
- Castro, C.A. (1997). Primacy and recency effects in Rhesus monkeys (Macaca mulatta) using a serial probe recognition task: II. Effects of atropine sulfate. Behav Neurosci, 111: 676-682.
- Castro, C.A., Gresham, V.C., Finger, A.V., Maxwell, D.M., Solana, R.P., Lenz, D.E. and Broomfield, C.A. (1994). Behavioral decrements persist in rhesus monkeys trained on a serial probe recognition task despite protection against soman lethality by butyrylcholinesterase. Neurotoxicol Teratol, 16: 145-148.
- Castro, C.A., Larsen, T., Finger, A.V., Solana, R.P. and McMaster, S.B. (1992).

  Behavioral efficacy of diazepam against nerve agent exposure in rhesus monkeys.

  Pharmacol Biochem Behav, 41: 633-638.
- Chen, K.K. and Rose, C.L. (1952). Nitrite and thiosulfate therapy in cyanide poisoning. JAMA, 149: 113-119.
- Eng, L.-I., L. (1962). Glucose-6-phosphate dehydrogenase activity in the red blood cells of monkeys. Nature, 195: 1110.
- Johnson, W.D. (1987). Effects of methemoglobin versus potassium cyanide intoxication. Final Report. Contract: DAMD17-83-C-3083. AD-B122 370.

- Levine, B.S., Wheeler, C.W. and Tomlinson, M.J. (1996). Acute and subchronic oral toxicity of the anticyanide drug WR242511 tartrate. The Toxicologist, 30:106-107.
- Marino, M.T., Peggins, J.O., Brown, L.D., Urquart, M.R. and Brewer, T.G. (1994). Pharmacokinetics and kinetic-dynamic modeling of an 8-aminoquinoline candidate anticyanide and antimalarial drug (WR242511). Drug Metabol Disp, 22: 358-366.
- Marrs, T.C. and Bright, J.E. (1986). Kinetics of methaemoglobin production (1). Kinetics of methaemoglobinemia induced by the cyanide antidotes p-aminopropiophenone, p-hydroxyaminopropiophenone or p-dimethylaminophenol after intravenous administration. Human Toxicol, 5: 295-301.
- Martin, D.G., Watson, C.E., Gold, M.B., Woodard, C.L. and Baskin, S.I. (1995). Topical anesthetic-induced methemoglobinemia and sulfhemoglobinemia in macaques: a comparison of benzocaine and lidocaine. J Appl Toxicol, 15: 153-158.
- Moe, G.K., Peralta, V. and Seevers, M.H. (1949). Central impairment of sympathetic reflexes by 8-aminoquinolines. J Pharmacol Exp Therapeut, 95: 407-414.
- Noker, P.E. (1994). Single dose iv and oral pharmacokinetics, bioavailability and metabolism study of WR242511 in dogs. Final Report. Contract: DAMD17-93-C-3004.
- Rockwood, G.A. (1998). Safety and behavioral efficacy of a methemoglobin former in nonhuman primates trained on the serial probe recognition task. Protocol 1-05-98-000-A-759. USAMRICD, Aberdeen Proving Ground, MD.
- Rockwood, G.A., Baskin, S.I., Romano, J.A. Jr., Murrow, M.L., Preville, J.A., Lee, R.B. and Sweeney, R.E. (1999). Comparison of hematologic consequences and efficacy of p-aminophenones in mice. Environ Toxicol Pharmacol, 7: 237-252.
- Rockwood, G.A., Armstrong, K.R., Machholz, I.J., Carpenter, C.B. and Baskin, S.I. (2000). Species comparison of methemoglobin reductase. The Toxicologist, 54: 207.
- Rockwood, G.A., Gold, M.B., Finger, A.V. and Baskin, S.I. (1999). The effects of sodium nitrite on methemoglobin formation in nonhuman primates. The Toxicologist, 48, 373-374.
- Schmidt, L.H. (1983). Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with plasmodium cynomolgi in rhesus monkeys. Antimicrob Agents Chemo, 24: 615-652.

- Schmidt, L.H., Fradkin, R., Vaughn, D. and Rasco, J. (1977). Radical cure of infections with plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am J Trop Med Hyg, 26, 1116-1128.
- Schmidt, I.G. and Schmidt, L.H. (1949). Neurotoxicity of the 8-aminoquinolines. J Comp Neurol, 91: 337-368.
- Transition Information Paper: WR242511 and WR269410 methemoglobin-formers as cyanide prophylactics for the soldier. Walter Reed Army Institute of Research, Washington, DC. December, 1994.
- Wiselogle, F.Y. (1946). A survey of antimalarial drugs. J.W. Edwards: Michigan, v.1.

# Appendix A. List of Project Participants

# List of participants (all participants affiliated with USAMRICD, APG-EA, MD, unless otherwise indicated)

#### **NAME**

Dr. Gary A. Rockwood Dr. Steven I. Baskin MAJ(P) Mark B. Gold

MAJ Kevin R. Armstrong
MAJ Crystal M. Briscoe
MAJ Steven M. Duniho
Dr. Ming L. Shih
J. Richard Smith
Steven Tucker
Anita V. Moran
David W. Kahler
Kenneth Mills
SGT Elton J. Machholz
SGT Matthew L. Jepsen
SGT Jason McKain

#### **NAME**

Dr. Robert Christenson

#### **DIVISION**

Drug Assessment Pharmacology Comparative Medicine

Comparative Medicine

Comparative Medicine Comparative Medicine

Pharmacology Pharmacology

Comparative Medicine

Drug Assessment
Drug Assessment
Comparative Medicine
Comparative Medicine
Comparative Medicine

Comparative Medicine Comparative Medicine

#### **AFFILIATION**

University of Maryland Clinical Chemistry Lab

#### **CONTRIBUTION**

PΙ

Collaborator

Collaborator, Veterinary

support

Veterinary support Pathology support Pathology support

Chemical analysis support Chemical analysis support

Clinical chemistry
Technician support
Technician support
Technician support
Veterinary technician support

Veterinary technician support Veterinary technician support Veterinary technician support

#### **CONTRIBUTION**

Clinical chemistry (hemoglobinuria determination)

## Appendix B. Timeline

#### **Protocol 759 Timeline**

1 April 1998

USAMRICD protocol approved: Safety and Behavioral Efficacy of a Methemoglobin Former in Nonhuman Primates Trained on the Serial Probe Recognition Task.

Protocol 1-05-98-000-A-759 (referred to as Protocol 759)

PI: G. A. Rockwood

13 May 1998

Sodium nitrite (19.0 mg/kg, iv) administered to an anesthetized male (16999, Byron).

14 May 1998

Sodium nitrite (16.0 mg/kg, iv) administered to an anesthetized female (B055, Nancy). 27 May 1998

Sodium nitrite (19.2 mg/kg, iv) administered to an anesthetized male (7AS, Astin).

10 June 1998 Sodium nitrite (19.4 mg/kg, iv) administered to an anesthetized male (JWO, Joe).

11 June 1998

Sodium nitrite (20/mg/kg, iv) administered to an anesthetized male (F942, Kong). 16 June 1998

Sodium nitrite (19.6 mg/kg, iv) administered to an anesthetized female (P3C, Sheba).

13 August 1998

WR242511 (3.5 mg/kg, iv, in PEG200) administered to P3C.

19 August 1998

WR242511 (3.5 mg/kg, iv, in PEG200) administered to 7AS.

20 August 1998

WR242511 (3.5 mg/kg, iv, in PEG200) administered to B055.

1 September 1998

WR242511 (3.14 mg/kg [due to catheter clog], iv, in PEG200) administered to JW0.

WR242511 (3.5 mg/kg, iv, in PEG200) administered to F942.

3 September 1998

WR242511 (3.5 mg/kg, iv, in PEG200) administered to 16999. 14 September 1998

PEG200 (iv) administered to 7AS.

15 September 1998

Chair only, no injection (F942).

24 September 1998

Administered new potential solvent, Multisol (iv) to 16999

29 September 1998

WR242511 (7.0 mg/kg, iv, in Multisol) administered to JW0

WR242511 (7.0 mg/kg, iv, in Multisol) administered to P3C.

1 October 1998

JW0 found dead in cage. Necropsy performed.

P3C observed in home cage - pale, labored breathing, in distress. Intervention by attending veterinarian. P3C survived.

29-31 October 1998

Pyrogen testing on WR242511, PEG200 and Multisol samples, by Celsis Laboratory Group.

30 October 1998

Steering Committee meeting at USAMMDA. Slow iv infusion, and/or oral administration recommended.

10 December 1998

Steering Committee meeting USAMMDA. Protocol 759 addenda presented: slow infusion (7.0 mg/kg, iv, in Multisol, administered across 1 hr) and oral administration (7.0 mg/kg, per os, in Multisol),

13 January 1999

WR242511 (7.0 mg/kg, iv, in Multisol) administered to F942 (anesthetized), using slow infusion (1 hr).

16 February 1999

Steering Committee meeting at USAMMDA and ICD (videoconference). Slow infusion study summary presented.

Recommendation: oral dosing, in a single WR242511-naïve rhesus.

24 February 1999

Drs Rockwood and Baskin from USAMRICD met with Dr. Heiffer and MAJ Bonner at WRAIR to discuss details for oral dosing. It was agreed upon to expose a single, WR242511-naïve male rhesus to 7.0 mg/kg, per os, in Multisol.

21 April 1999 WR242511 (7.0 mg/kg, per os, in Multisol) administered to a WR242511-naive male rhesus (6VY, Adams). Procedure performed with animal under light anesthesia.

25 April 1999

6VY found dead in cage.

26 April 1999

Necropsy performed on 6VY.

3 May 1999

Multisol (per os) administered to 16999. Procedure performed with animal under light anesthesia.

17-18 May 1999

Mass spectrometry analyses conducted at USAMRICD on WR242511 solutions and on Multisol

19 May 1999

Steering Committee meeting at USAMMDA. Oral WR242511 study summary presented, including pathology results.

# Appendix C. Test Articles

#### **Test Articles**

Sodium Nitrite Source: Sigma

WR242511-AE Source: Walter Reed Army Institute (ICD # 1359) of Research (WRAIR)

Quantity: ~10 g
Bottle No.: BM05816
Manuf. Code: DJD-08-235

Date received at USAMRICD: May 1998

PEG200 Source: Sigma Components: Polyethylene glycol

Multisol Source: Prepared in-house

Components: Water: 48.5%
Propylene glycol: 40.0%
Ethanol: 10.0%

Benzyl alcohol:

1.5%

# Appendix D. Animal Histories

#### Sheba, RH P3C Female Rhesus

Drug Procedure History Medical History,

28FEB95 to 30 APR 98 Ketamine / Xylazine IM Anesthesia For TB test /Physical Exams (X 13)

28APR95 Ivermectin PO for Intestinal Parasites

28 JUN95 to 30JUN95 Buprenorphine IM for Pain due to abscess

28JUN95 to 7JUL95 Cephazolin PO Antibiotic for abscess

24JUL95 Ketamine / Xylazine IM Anesthesia for IRRADIATION Total Dose 700 rads whole body

24JUL95 to 6AUG95 "SC" compound SQ QID

31JUL95 to 6AUG95 Rocephin 250 mg IV QID

31JUL95 to 6AUG95 Gentocin 10 mg SQ QID

7AUG95 to 18AUG95 Tintin 125 mg SQ BID

19SEP95 to 25SEP95 Flagyl PO for Giardia

18DEC97 Ketamine anesthesia IM, Kidney Transplant Donor Cepha/Torbogesic IM TID x 2 days

18MAY98 to 30AUG99 Telazol 3 mg/kg IM Anesthesia Physical exams TB test

16JUN98 Telazol/Isoflurane Anesthesia 19.2 mg/kg NaNO<sub>2</sub> IV

13AUG98 WR242511 3.5 mg/kg IV

29SEP98 WR242511 7.0 mg/kg IV

#### Nancy RH 90B055 Female Rhesus

Drug Procedure History Medical History,

23SEP91 to 30 AUG99 Telazol or Ketamine IM Anesthesia for Physical Exam, TB test, blood (X 47)

9DEC91 Ivermectin PO Whip worms

11MAY92 Telazol Anesthesia, SEB Toxoid Exposure

11JUN92 Telazol Anesthesia (blood for SEB antibodies)

16JUN92 Telazol Anesthesia SEB Exposure Aerosolized

2SEP92 to 21SEP95 Telazol anesthesia Trachobronchial Lavage (X 5)

23MAY93 to 29MAY93 Bactrium PO SID

24MAY93 Telazol anesthesia Telemetry Unit implant

18JUL95 Telazol anesthesia Anthrax Exposure

31AUG95 Telazol anesthesia Anthrax Exposure

2SEP95 to 7SEP95 Telazol anesthesia Blood Cultures

14MAY98 Telazol/Isoflurane Anesthesia Exposure 16.0 mg/kg NaNO2 IV

20AUG98 Exposure WR242511 3.5 mg/kg IV

#### Byron RH16999 Male Rhesus

Drug Procedure History Medical History,

10SEP93 to 21SEP99 Telazol or Ketamine IM Anesthesia PE, TB test, Blood (X 45)

27DEC93 to 5FEB94 Telazol or Ketamine Exposure to unknown experimental substance

18MAY94 Telazol anesthesia Plethygmograpgy, Exposure SEB Aerosol exposure (5 LD<sub>50</sub>)

18JUL95 Telazol anesthesia Vaccinated Anthrax

24AUG95 Telazol anesthesia Tracheobroncho Lavage

30AUG95 Telazol anesthesia Exposure Anthrax

14MAY96 to 17MAY96 Telazol anesthesia ID Exposure to unknown substance

13MAY98 Telazol/Isoflurane anesthesia Exposure 19.0 mg/kg NaNO2 IV

3SEP98 Exposure WR242511 3.5 mg/kg IV

24SEP98 Exposure Multisol IV

3MAY99 Exposure Multisol Oral

#### Kong RHF942Male Rhesus

Drug Procedure History Medical History,

9NOV87 to 3NOV98 Ketamine or Telazol Anesthesia for PE, TB test, Blood (X 37)

22NOV87 to 23NOV87 Polyflex IM

24NOV87 to 27JAN88 Tilamin 100 mg PO SID

3MAY88 to 29JUN88 Ketamine Biotal PE, Blood, TB test (X 9)

3MAY88 Ketamine/Biotal Anesthesia "BM" Aspertate Exposure, Irradiation (unk dose)

6JUN88 to 11JUN88 Exposure 0.5 ml "GF" SQ

29MAY to 6JUN88 Exposure 0.5 ml "GF" SQ

31JUL92 to 13AUG92 3.5 ml Bactrin PO BID

14SEP92 Acepromazine, Meperidine, Narcan

1JAN94 POSITIVE HERPES (Ocular)

14SEP95 Ketamine anesthesia Endoscopy

11JUN98 Telazol/Isoflurane anesthesia Exposure 20 mg/kg NaNO2 IV

1SEP98 Exposure 3.5 mg/kg WR 242511 IV

7JAN98 Exposure Telazol Only MHb

13JAN98 Exposure WR242511 7.0 mg/kg IV SLOW (60 minutes)

#### JOE RHJW0 Male Rhesus

Drug Procedure History Medical History,

31MAR94 to 28AUG98 Ketamine or Telazol anesthesia for PE, TB test, Blood (X 28)

29AUG94 Ketamine anesthesia Exposure "MDGFASC"

30AUG94 to 7 SEP94 Exposure "WO" SQ SID

1SEP94 Ketamine/Xylazine Bone Marrow Aspiration

31OCT94 to 1NOV94 Exposure 2 ml "BM" Aspirate

11DEC95 Flagyl PO Intestinal Parasites

11DEC95 to 18DEC95 125 mg Metrandazol PO Fecal Bacteria

10JUN98 Telazol/Isoflurane anesthesia Exposure NaNO2 IV 19.4 mg/kg

1SEP98 Exposure WR242511 3.5 mg/kg IV

29SEP98 Exposure WR 242511 7.0 mg/kg IV (Died)

#### **ASTIN RH7AS Male Rhesus**

Drug Procedure History Medical History.

18AUG89 to 21SEP99 Ketamine or Telazol anesthesia for PE, TB test, Blood (X 49)

27MAY98 Exposure 19.2 mg/kg NaNO2 IV

19AUG98 Exposure WR242511 3.5 mg/kg IV

14SEP98 Exposure PEG 200 IV

#### **ADAMS RH6VY Male Rhesus**

Drug Procedure History Medical History,

17AUG89 to 23MAR99 Ketamine or Telazol anesthesia for PE, TB test, Blood 10MAR98 Ketamine/Acepromazine anesthesia Exposed to 3.3 mg Physostimine IV 8JUN98 Ketamine/Acepromazine anesthesia Exposed to 3.3 mg Physostimine IV 31AUG98 Ketamine/Acepromazine anesthesia Exposed to 3.3 mg Physostimine IV 15SEP98 Ketamine/Acepromazine anesthesia Exposed to 3.3 mg Physostimine IV 17NOV98 Ketamine/Acepromazine anesthesia Exposed to 3.3 mg Physostimine IV 02MAR99 Ketamine/Acepromazine anesthesia Exposed to 3.3 mg Physostimine IV 21APR99 Telazol anesthesia Exposed to WR242511 7.0 mg/kg Orally 25APR99 Deceased

# Appendix E. Hematologic Data (NaNO<sub>2</sub>)

Methemoglobin Sampling Table 27MAY98 NaNO<sub>2</sub>

11:40	******				Martin Ma			X	- 10 CO		The state of the s
1:40	from inj		<b>K</b>	<b>£</b>	Ŝ,	0 ∰	MHb	THP	HPO <sub>2</sub>	HPCO	MHb
	0	0	1643	11.5	99.2	-0.2	0.4	11.0	99.3	6.0-	0.7
			1644	11.3	99.2	-0.1	0.3	11.3	99.1	6.0-	80
12:01	9	4.0	1645	11.0	97	-0.1	2.5	10.9	6.96	8.0-	2.9
12:06		4.0	1646	10.8	6.96	-0.2	2.6	10.7	- 26	-1.0	2.9
12:10	18	4.0	1647	10.6	96.1	-0.4	3.6	10.7	96.3	-0.8	3.6
			1648	11.0	96.2	-0.4	3.4	10.6	96.3	-0.9	3.6
			1649	10.9	96.3	-0.4	3.4	10.7	96.3	6.0-	3.6
12:37	13	7.0	1650	10.5	93.9	-0.5	5.8	10.1	94	-0.9	5.9
			1651	10.5	93.9	9.0-	5.8	10.3	93.8	-1.1	6.2
			1652	10.4	94.0	-0.5	5.7	10.3	93.9	-1:1	0.9
1302	16	10.0	1653	9.0	92.1	-0.7	7.7	8.9	616	-1.3	8.1
			1654	9.0	92.1	-0.7	7.7	9.0	92.1	-1.2	7.9
			1655	9.0	92.2	-0.7	7.6	9.0	92.3	-	7.7
3:27	15	12.4	1656	9.2	91.1	-0.7	9.8	9.2	91.5	-1.2	9.8
			1657	9.3	91.4	2.0-	8.4	9.2	91.6	-1.2	8.5
			1658	9.4	91.5	9.0-	8.3	9.2	91.6	-1.1	8.4
1347	_	15.6	1659					9.5	90.2	-1.1	8.6
		Post	1660	9.5	6.68	-0.7	8.6	9.4	90.1	-1.2	6.6
	,	Arrest	1661	9.5	90.1	-0.7	9.6	2.6	90.1	-1.2	8.6
14:03	97	15.6	1662	9.4	89.2	9.0-	10.4	9.3	89.3	1:1-	10.7
			1663	9.3	89.3	-0.8	10.4	9.4	89.4	-1.2	10.6
8			1664	9.2	89.5	9.0-	10.2	9.3	9.68	-1.1	10.4
14:28	13	17.4	1665	8.9	89.3	-0.5	10.4	9.0	89.2	-1.2	10.8
			1666	8.9	89.4	-0.7	10.4	9.1	89.5	1.3	10.6
1			1667	9.0	89.4	0.7	10.3	9.3	89.4	-1.4	10.7
14:52	14	19.2	1668	9.1	8.68	-0.5	6.6	9.0	8.68	1.1-	10.3
			1669	9.3	9.68	8.0-	10.2	9.1	6.68	-1.0	10.1
;			1670	9.1	8.68	-0.6	10.0	9.1	6.68	-1.3	10.2
10:01		19.2	1671	9.3	89.7	-0.7	10.0	9.0	6.68	-1.I	10.2

Methemoglobin Sample Table 13MAY98 NaNO2

·	-		т		_		_		-	<del>,</del>			_					_	,
	MHb	9.0	0.5	4.1	4.2	5.5	5.4	7.7	7.9	10.0	10.1	12.6	12.1	12.5	12.6	15.2	15.4	15.3	
OSM3 2 (Print)	HPCO	-0.7	-0.7	-0.8	-1.0	-0.8	-0.8	-0.8	-0.8	-0.8	-0.8	-0.8	-1.5	-0.7	-0.9	-0.8	-1.0	-0.8	
OSM3	HbO <sub>2</sub>	99.2	99.4	95.8	95.7	94.4	94.4	88.1	87.6	85.8	85.8	82.3	86.5	82.2	82.1	79.5	78.9	78.8	
	THP	1:11	0.11	10.1	10.2	10.4	10.5	10.0	8.6	8.6	6.6	8.6	10.1	6.6	6.7	8.6	8.6	8.6	
	MHb	0.4	0.4	3.7	3.8	5.1	5.1	7.6	7.4	6.7	9.6	12.2	12.1	12.1	12.2	14.7	15.0	15.0	
OSM3 1 (no print)	HPCO	-0.3	-0.3	-0.2	-0.4	-0.3	-0.4	-0.4	-0.3	-0.4	-0.3	-0.4	-0.4	-0.4	-0.4	-0.3	-0.3	-0.4	
OSM3 1	<sup>2</sup> 09H	99.3	99.3	95.9	95.9	94.5	94.6	87.8	87.9	85.6	85.4	82.5	82.4	82.2	82.0	79.2	6.87	78.7	
	THb	11.1	11.1	10.3	10.2	10.7	9.01	10.3	10.2	10.0	10.0	10.1	10.0	10.1	10.0	6.6	10.0	10.0	
8	<b>≱</b> t:	1608	6091	1610	1611	1612	1613	1614	1615	9191	1617	1618	1619	1620	1621	1622	1623	1624	
NaNO,		0		5.2		7.8		10.4		13.0		16.0				19			
Time	fin mon	0		33		15		27		-18		17				12			
Time		12:15		13:03		13:22		14:01		14:28		14:50				15:06			

### **JOE RHJW0 Male Rhesus**

Methemoglobin Sample Table 10JUN98 Exposure NaNO2 IV 19.4 mg/kg

Ime	, me	Nan ONan	Sam.		CSM3	OSM3 I (no print)	_		OSM3	OSM3 2 (Print)	
80	from inj		#	THP	HbO <sub>2</sub>	HPCO	MHB	THB	HbO,	HPCO	MHh
11:49	0	0	1674	9.6	99.1	-0.5	9.0	9.4	99.3	-1.0	9.0
1			1675	9.6	99.2	-0.5	0.5	9.5	99.2	-1:1-	8.0
ı,			1676	9.5	99.3	-0.5	0.5	9.4	99.3	-1.1	8.0
12:13	13	4.2	1677	10.3	97.4	-0.2	2.3	10.1	97.4	-1.0	2.6
- 1			1678	10.1	97.3	-0.4	2.4	6.6	9.76	-0.9	2.4
			1679	10.0	97.3	-0.4	2.3	6.6	97.3	-1.1	13.4
12:27	14	7.4	1680	6.6	97.0	-0.4	2.7	10.0	97.0	-1.0	3.0
-			1681	8.6	97.1	-0.4	2.6	10.0	2.96	-1-	3.2
12:45	24	7.4	1682	10.2	95.5	-0.4	4.2	10.1	95.3	-1.1	4.7
			1683	10.3	95.4	-0.4	4.3	10.1	95.2	-1.2	4.8
			1684	10.2	95.4	-0.4	4.3	10.2	95.3	-I:I-	4.7
3:20	14	11.0	1685	6.6	93.6	-0.4	6.1	10.2	93.5	-1.1	6.5
1			1686	10.1	93.8	-0.4	5.9	6.6	93.7	-1.3	6.3
Ι,			1687	10.2	93.8	-0.4	5.9	10.0	93.8	-1.2	6.3
13:51	14	14.6	1688	8.6	92.1	-0.3	7.6	6.7	91.8	-1.0	8.2
			1689	6.6	92.3	-0.3	7.4	6.7	92.0	-1.1	8.0
Ţ,	,		1690	6.6	92.2	-0.4	7.5	8.6	91.8	-1.2	8.2
14:24	14	17.2	1691	9.3	90.54	-0.6	9.2	9.1	8.06	-1.3	9.3
T			1692	9.5	8.06	-0.7	9.0	9.3	8.06	-1:1	9.2
T,			1693	9.6	8.06	-0.7	9.0	9.1	8.06	-1.2	9.2
14:52	14	19.4	1694	9.2	6.68	-0.7	6.6	9.1	90.0	-1.2	10.1
T			1695	9.2	868	-1.0	10.1	9.2	90.1	-1.2	6.6
T.			1696	9.1	8.68	-1.0	6.6	9.1	90.3	-1.1	9.7
15:03	25	19.4	1697	9.1	90.1	-0.8	2.6	9.0	90.4	-0.8	9.5
T			1698	9.2	90.2	-0.9	9.6	9.1	90.4	-1.2	6.7
			1699	0.6	90.3	-0.7	9.5	9.1	90.3	-1.3	6.7

Methemoglobin Sample Table 11JUN98 Exposure 20 mg/kg NaNO<sub>2</sub> IV

(no print)
# I'MO HOUZ HOUD I
12.5 99.1
12.4
1705 12.4
11.9
1707 12.1 97.1 -0.4
11.8
11.4
1710 11.6 96.1
10.8
10.9
1713 10.9
10.8 94.0 -0.6
11.1 94.0 -0.6
1716 10.8 94.1 -0.7
10.5 92.2 -0.7
10.4 92.2
1719 10.5
10.0 90.8
10.3 91.0
1722 10.4
9.6
10.0 90.0
1725 9.9 90.10.8 9.7

Methemoglobin Sample Table 14MAY98 NaNO2 IV

15. 3	T A. S.	1	_		_	-			-	1			_		_					
	MHP	0.8	80				4.1	4.0		6.5	13.4	9.6	9.3	9.3	12.3	12.1	13.3	13.2	15.6	15.5
OSM3 2 (Print)	HPCO	-0.9	-0.9				-1.0	-1.0		6.0-	-1.1-	-1.2	-1.1	-1.1	-1.4	-1.3	-1.3	-1.3	-1.4	-1.5
<b>EMSO</b>	HbO <sub>2</sub>	99.2	99.2				95.8	96.0		93.4	93.4	90.5	9.06	9.06	87.8	87.9	8.98	86.8	84.5	84.6
	,THb	11.0	10.9				10.5	10.4		6.6	10.3	10.0	10.0	10.1	10.0	6.6	6.6	6.7	6.6	6.7
	MHP	0.4	0.5	3.9	2.4	3.0	3.7	3.7	5.2	6.4	6.2	9.2	9.1		12.1	11.9	13.3	13.1	15.3	15.4
(no print)	HbCO	-0.4	-0.4	0.1		-0.5	-0.5	-0.5	-0.7	9.0-	9.0-	9.0-	-0.7		-1.0	-1.0	-1.2	-1:1	-1:1	-1.2
	<b>33</b>	99.4	99.2	95.4		296.7	96.1	0.96	94.7	93.4	93.5	9.06	200.7		87.9	88.0	8.98	8.98	84.7	84.7
	THP	11.1	11.2	10.5		9.01	10.6	10.6		10.3	10.1	10.0	10.1		8.6	10.0	8.6	10.0	6.6	8.6
Sam.	#	1626	1627				1628	1629		1630	1631	1632	1633	1634	1635	1636	1637	1638	1639	1640
NaNO.		0		4.0	4.0	4.0	4.0		7.0	7.0		10.0			11.6		13.0		16.0	
Time		0		2	9	10	25		4	12		<b>&amp;</b>			13		8		19	
Time		10:00		10:13	10:17	10:21	10:33		10:46	10:52		11:10			11:35		12:02		12:28	

## Sheba, RH P3C Female Rhesus

Methemoglobin Sample Table 16JUN98 NaNO2

Time	Time	NaNO	Sam:		OSM3 I	OSM3 I (no print)			OSM3	OSM3 2 (Print)	
	fin mon		AL:	THP	HbO	HBCO	MHb	田田	HhO.	HECO	MHh
11:04	0	0	1728	11.8	99.0	-0.4	0.4	11.6	99.1	-	
			1729	12.0	6.86	-0.4	0.5	11.6	0.66		0.7
			1730	11.7	8.86	-0.4	9.0	11.8	98.9	-	0.7
11:32	20	4.4	1731	10.8	93.9	-0.5	2.9	10.9	94.0	-0.9	2.9
			1732	10.7	94.0	-0.3	2.8	10.6	94.1	-0.8	2.8
			1733	10.9	93.8	-0.5	2.9	10.5	93.9	-1.0	3.1
12:00	21	8.4	1734	10.5	91.0	-0.4	5.7	10.7	8.06	-0.9	0.9
			1735	10.8	91.0	-0.4	5.6	10.7	91.0	6.0-	5.8
			1736	6'01	8.06	-0.4	5.7	10.6	6.06	-	5.9
13:34	19	11.2	1737	10.3	90.7	9.0-	9.9	10.6	90.6	-1.0	6.7
			1738	10.7	91.0	-0.5	6.4	10.4	91.1	-1.0	6.5
			1739	10.6	8.06	-0.5	6.5	10.4	6.06	-1.2	8.9
13:04	<u>&amp;</u>	14.8	1740	9.6	91.2	-0.7	7.6	9.3	91.5	-1.1	7.5
			1741	6.7	91.5	9.0-	7.3	9.3	91.5	-1.2	7.6
,			1742	9.7	91.4	-0.5	7.4	9.4	91.5	-1.2	7.6
13:35	81	18.4	1743	8.6	90.1	-0.7	8.5	10.0	6.68	-1.2	8.8
			1744	10.0	90.2	9.0-	8.4	6.6	6.68	-1.4	8.9
			1745	8.6	0.06	-0.8	9.8	6.6	90.0	-1.3	8.8
14:08	18	9.61	1746	10.7	90.3	-0.7	7.7	10.7	868	-1.1	7.9
			1747	11.1	90.3	-0.6	7.5	10.7	90.3	-1.2	7.7
			1748	10.8	90.4	9.0-	7.4	10.8	90.3	-1.0	7.5
						1		1			

Appendix F. Hematologic and Blood Chemistry Data (WR242511)

## **ADAMS RH6VY Male Rhesus**

Adams RH6VY WR242511 7.0 mg/kg PO 21APR99

_		Т	_		_	_	_	1		_	_	<b>-</b>	
		3	<u>ت</u>	:			77		<u> </u>		=		
		1	4	1	0.4	,	3.0	,	3.5	2	3		
		Ž	Z	160	2		0	5	133	150	000		
		CCDT	בַּבְּבְּי	121	91	71	0	9	73	3.6	20		
		CPK	7	300	077	618	010	000	000	302	700		
emistr		CRE		52		80		× ×		0.5			
um ch		BUN		11.7				18.4	. U.T	16.8	200		
and serum chemistry		GLU		_		69	,	116	,	120			
Hematology a	3	MCHC		32.6		32.5		33.0		32.8		32.2	!
Ħ	1	MCH		8.4.8	,	24.6		25.2		25.0		24.7	
	Carri	×BC		2.63		7.77	,	10.6		0.11		6.74	
	451	955	1 2 3	13.3		15.2	,	10.0		13.0		15.7	
	TOL	וטם	L 71	40.		40./	107	48.4	200	C./+	9	48.9	
	Jaa	NDC	212	0.13	212	0.17	600	0.33	100	0.71	,	6.36	
	Simo	2	000	asc	1	=	177	<b>.</b>	245	2411	107	48n	

## **ADAMS RH6VY Male Rhesus**

Methemoglobin Sample Table 21 APR99

ZIAPK99	6													
Time	Time from in:	Sam.			OSM3 A					OSIA	OSM3 B		1	
		#=	THP	HbO <sub>2</sub>	HPCO	MHb	Oct	Sample	THP	HbO,	HPCO	MHh	120	سم ،
21APR99	Base	5532	15.2	49.4	0.0	0.4	10.4	1985	15.4	51.3	-0.7	0.6	130	
		5533	15.1	49.8	-0.1	9.0	10.5	1986	15.3	51.4	-0.8	0.6	10.0	
	+1h	5534	15.2	34.3	0.1	0.5	7.2	1987	15.8	32.8	-0.5	9.0	7.2	-,-
		5535	15.4	34.3	0.2	0.5	7.3	1988	15.4	35.6	-0.5	0.3	7.6	.,.
	49+	5536	15.9	18.2	0.2	0.7	4.0	1989	16.2	18.3	-0.4	0.6	4.1	
		5537	15.8	20.6	0.2	0.5	4.5	1990	191	203	-0.4	800	1.5	
22APR99	+24h	5538	15.2	29.8	0.2	0.7	6.3	1661	15.4	31.0	50-	800	4.7	· · ·
		5539	15.3	29.1	0.2	9.0	6.2	1992	15.5	20.8	5.0-	0.0	0.0	
23APR99	+48h	5540	15.6	43.4	0.1	0.7	9.4	1993	15.2	44.6	-0.5		0.4	
		5541	16.2	38.8	0.1	0.7	8.7	1994	15.8	41.7	50-	0.1	7.7	
24APR99	+72h	5543	15.7	15	0.5	9.0	3.3	9661	15.6	8 91	- 0	90	2.6	
		5544	15.6	15.7	0.5	0.7	3.4	1997	13.9	20.3	-0.2	0.0	3.0	
-				,						_				

19AUG98 WR242511 3.5 mg/kg

_						,			·
	C	104		101	106	111		111	
	×	5.0		5.0	3.5	40	000	4.2	
	Na	152		129	152	155	150	152	
	SGPT	75	120	77	123	129	102	87	
	SGOT	81	268	127	16	114	54	09	
V	CPK	1175	11570	4443	583	1354	194	117	
chemistry	CRE	1.4	0.8	1.2	1.2	1.3	1.2	1.4	
and serum c	BUN	13.2	17.0	10.5	11.8	9.7	13.4	15.3	
y and s	GLU	57		62	79	55	65	64	
Hematology a	MCHC	31.8	32.0	33.4	33.3	37.6	32.5	35.1	
He	MCH	22.4	22.2	23.6	23.8	25.1	23.2	24.9	
	WBC	5.65	12.6	9.32	7.33	5.86	4.81	6.76	
	HGB	16.0	14.7	15.6	14.8	18.7	13.4	14.0	
	HCT	50.4	45.7	46.7	44.6	49.6	41.2	39.9	
	RBC	7.15	6.59	6.63	6.23	7.42	5.78	5.62	
	Time	Pre	49+	+24h	+48h	+120h	+168h	+288h	

14SEP98 PEG 200

	D	;	104	-	Ž		Γ
	×	1	3.2	:	pu		
	N.		149		pu		
	SGPT		55		53		
	SGOT		43		99		
ry	CPK		09		nd		
chemist	CRE		1.2		nd Du		
serum	BUN	Ī	12.4		6.11		
yy and	GLU		57	ŀ	pu		
Hematology and serum chemistry	MCHC		33.2	,	34.6		
H	MCH	000	23.3	1	24.6		
	WBC	,	0.32	,	6.33		
	HGB	, , ,	14.4		14.3		
	HCT	0 07	43.3	7 1 7	41.4		
	RBC.	117	0.10	60.3	2.02	,	
	<b>Fime</b>	CIDY	MOE	1 1 1			

19AUG98 3.5 mg/kg WR242511 Methemoglobin Sample Table

# 1Hb HbO <sub>2</sub> 1768 15.4 48.2 1769 14.8 29.1 1772 14.3 41.9 1773 14.2 42.2 1774 14.0 30.2 1775 14.6 29.9 1775 14.6 29.9 1778 13.8 40.4 1779 14.8 38.5 1786 14.0 31.7 1792 13.4 24.2 1793 13.3 24.4 1796 13.4 41.7 1797 13.5 41.1 1801 13.2 19.2 1805 12.7 50.4 1806 12.7 50.4 1810 12.8 24.4 1811 12.9 68.9	HbCO -0.4 -0.4 -0.4 -0.3 -0.3 -0.3 -0.4 -0.4 -0.4 -0.4 -0.5 -0.5 -0.5 -0.5 -0.5 -0.6 -0.6 -0.6 -0.6 -0.6 -0.6 -0.6 -0.7	MHb 0.4 0.5 0.6 0.7 0.8 0.8 1.1 1.1 1.2 1.5 1.5 1.5 1.7	02ct 10.3 6.0 8.3 8.3 8.3 8.3 6.1 6.1 6.1 6.1 6.1 4.5 7.7	14.7 14.7 15.0 15.0 13.6	HbO <sub>2</sub> 28.7 28.2 28.2 30.4 30.4 40.4	0.0 0.0 0.1 0.1	0.4 0.8 0.8 0.8 1.1	8.8 8.9 5.9 6.0 6.0
15.4 14.8 14.0 14.0 14.0 14.0 14.0 14.0 14.0 13.3 13.3 13.3 13.2 13.3 13.2 13.3	-0.4 -0.6 -0.3 -0.3 -0.3 -0.4 -0.4 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5	0.4 0.5 0.6 0.7 0.7 0.8 0.8 1.1 1.1 1.2 1.5 1.5	6.0 8.3 8.3 8.3 8.3 6.1 6.1 6.1 6.1 6.1 6.1 6.1 7.7 7.5 6.2 6.2 6.1 6.1 7.7 7.7 7.5 7.5 7.7 7.7 7.5 7.9 7.9 7.9 7.9 7.9 7.9 7.9 7.9	15.3 14.7 15.0 13.6 13.8	28.7 28.2 28.2 30.4 30.4	0.0 0.1 0.1	0.8 0.8 1.1 1.3	6.0
14.8 14.3 14.0 14.0 14.0 14.0 14.0 14.0 13.3 13.3 13.3 13.2 13.2 13.2 12.7 12.9 12.9 12.9	-0.6 -0.4 -0.3 -0.3 -0.3 -0.4 -0.4 -0.5 -0.6 -0.6 -0.6 -0.6	0.5 0.6 0.7 0.6 0.7 0.8 1.1 1.1 1.2 1.5 1.5 1.5	6.0 8.3 8.3 8.3 8.3 6.1 6.1 6.1 6.2 6.2 6.1 6.1 7.7 7.7 7.7 7.7	14.7	28.2 28.2 30.4 23.2	0.0 0.1 0.1	0.8 0.8 1.1 1.3	8.8 5.9 6.0 6.0
14.3 14.0 14.0 14.0 14.0 14.0 14.0 13.3 13.3 13.3 13.2 13.2 12.7 12.9 12.9 12.9	-0.4 -0.5 -0.3 -0.3 -0.3 -0.4 -0.4 -0.4 -0.5 -0.5 -0.6	0.6 0.7 0.6 0.8 0.8 1.1 1.1 1.2 1.5 1.5 1.5	8.3 8.3 8.3 8.3 6.1 7.7 6.1 6.1 6.1 6.1 7.7 7.7	15.0	28.2 28.2 30.4 23.2 40.4	0.0	0.8 0.8 1.1 1.1	8.8 5.9 6.0 6.0
14.2 14.6 13.8 13.8 14.0 14.0 13.4 13.3 13.4 13.5 13.0 12.7 12.9 12.9 12.9	-0.5 -0.2 -0.3 -0.6 -0.4 -0.4 -0.4 -0.5 -0.5	0.6 0.6 0.7 0.8 0.8 1.1 1.1 1.2 1.5 1.5	8.3 5.9 6.1 7.7 7.5 6.1 6.1 6.1 7.7	15.0	28.2 30.4 23.2 40.4	0.1	1.1	6.0
14.0 14.6 13.8 14.0 14.0 13.4 13.3 13.4 13.5 13.0 12.7 12.9 12.9 12.9	-0.2 -0.3 -0.5 -0.4 -0.4 -0.4 -0.4 -0.5 -0.5	0.6 0.7 0.8 0.8 1.1 1.1 1.2 1.5 1.4 1.7	5.9 6.1 7.7 7.5 6.2 6.1 6.1 4.5 7.7	15.0	28.2 30.4 23.2 40.4	0.1	1.1	6.0
14.6 13.8 14.0 14.0 13.4 13.3 13.4 13.5 13.0 12.7 12.9 12.9 12.9	-0.3 -0.5 -0.6 -0.4 -0.4 -0.4 -0.5 -0.5	0.8 0.8 1.1 1.1 1.2 1.5 1.4 1.7	6.1 7.7 7.5 6.2 6.1 6.1 4.5 7.7	13.6	30.4 23.2 40.4	0.1	1.1 1.3	6.0
13.8 14.0 14.0 13.4 13.3 13.4 13.5 13.0 12.7 12.9 12.9 12.9 12.9	-0.5 -0.6 -0.4 -0.4 -0.4 -0.6 -0.5 -0.5	0.8 1.1 1.2 1.5 1.7 1.7	7.7 7.5 7.5 6.1 6.1 4.5 7.7	13.6	30.4 23.2	0.1	1.1	6.0
14.8 14.0 14.0 13.4 13.3 13.4 13.5 13.0 12.7 12.9 12.9 12.9 12.9	-0.6 -0.3 -0.4 -0.4 -0.5 -0.5 -0.5	1.1 1.2 1.5 1.7 1.7 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	6.2 6.1 6.1 4.5 7.7	13.6	23.2	0.1	1.1	6.0
14.0 14.0 13.4 13.2 13.2 13.2 12.7 12.9 12.8 12.9 12.9	-0.3 -0.4 -0.4 -0.6 -0.5 -0.5	1.1 1.2 1.2 1.4 1.7 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	6.2 6.1 4.5 7.8	13.6	30.4 23.2 40.4	0.1	1.1	6.0
14.0 13.4 13.5 13.5 13.0 12.7 12.9 12.9 12.9	-0.4 -0.4 -0.6 -0.5 -0.3	1.2	6.1	13.6	23.2	0.1	1.3	4.4
13.4 13.3 13.5 13.5 13.0 12.7 12.9 12.9 12.9 12.9	-0.4 -0.6 -0.5 -0.3	1.5	4.5	13.6	23.2	0.1	1.3	4.4
13.3 13.4 13.5 13.0 12.7 12.9 12.9 12.8 12.9	-0.4 -0.5 -0.3	1.7	7.8	13.8	40.4		1.4	7.7
13.4 13.5 13.0 12.7 12.9 12.9 12.8 12.9	-0.6	1.7	7.8	13.8	40.4		1.4	7.7
13.5 13.2 13.0 12.7 12.9 12.8 12.8 12.9	-0.5	1.5	77			٦		
13.2 13.0 12.7 12.9 12.8 12.8 12.8	-0.3		-					
13.0 12.7 12.9 12.9 12.8 12.9 11.9	,,,	<b>1.4</b>	3.5	13.6	14.4	0.2	13	7.7
12.7 12.9 12.8 12.8 12.9 11.9	-0.3	1.3	3.5					
12.7 12.9 12.8 12.3 12.9	8.0-	1.5	0.6	12.9	49.9	-0.3	1.2	8 0
12.9 12.8 12.3 12.9	9.0-	1.4	8.9	13.0	50.1	-0.3		1 6
12.8 12.9 11.9	-0.5	1.3	4.6	13.1	24.0	0.1	6.0	4.4
12.3	-0.4	1.3	4.3	12.9	250	0.0	6.0	4.5
12.9	-0.8	1:1	11.9	12.8	68.0	-0.3	6.0	12.1
11.9	6.0-	1:1	12.4	13.2	67.7	-0.4		12.4
	-0.7	1.1	7.6	12.0	45.0	0.0	0.7	7.5
				12.1	44.7	0.1	9.0	7.5
13.2	-0.7	6.0	9.8	13.5	45.4	-0.2	0.8	8.5
13.7	-0.5	6.0	5.1	14.0	25.7	0.1	0.5	5.0
1823 13.8 27.3	-0.5	8.0	5.2	14.0	26.5	0.1	0.5	5.2

## Methemoglobin Sample Table 14SEP98 PEG 200

	Ī				1	1
	1 20	0 9	3	12	0.1	
	MHh	0.4	;	20	C:0	
M3 2 (no pri	HMCO	00		0.0	0.0	
ő	HbO,	34.1		30.3	2.00	
	THB	14.5		146	2	
	0,0	6.9	7.4	5.9	5.9	
(au	MHb	9.0	9.0	0.5	0.5	
OSM3 1(Pr	HPCO	-0.5	-0.5	-0.3	-0.4	
	Hb0,	35.4	38.2	30.3	30.2	
	THP	14.1	14.0	14.1	14.1	
Sam.	Ħ	1892	1893	1894	1895	
Time		BASE		+1hr		
Time		14SEP98				

### 03SEP98 WR242511 3.5 mg/kg IV

_				_		,		_		_	_	,	
	2	) [0]	2	×	:	106	20.1	115	:	112	7	106	
	×	3.5	j.	XX		3.4	;	4		3.3	;	4.3	:
	Z	151	101	XX		151		147		143		153	
	SGPT	52	3	37		84		83		50		57	
	SGOT	35	3	101		45	!	28		43		46	
	CPK	96	2	435		89		77		124		142	
nistry	CRE.	1.6		×		1.7		9:1		=		1.2	
l serum chemistry	BUN	13.3		20.9		13.6		12.8		16.2		16.4	
ū	19	81		×		71	30	80		66		84	
Hematology a	MCHC												
Her	MCH												
	WBC	7.9		14.0	000	8.8/	500	50.6	000	10.2		10.6	
	HGB	13.1		13.4	:	×	200	17.3		17.6		17.0	
	HCT	39.2		41.2	2	33.0	27.0	0.70	0 / 0	36.9	2 2 5	33.3	
	RBC	90.9	6 30	0.30	200	5.39	4 0 1	7.01	01.4	5.70	2 47	5.47	
	Time	Base	1745	T24II	1001	+12011	1111h	114411	1071	+1050	1001	±192n	

### 24SEP98 Exposure Multisol IV

		SGOT   SGPT   Na   K   C!	41	37 47		57 64 147 48 105		78 60 148 41 105	,,,
		CPK		105		316		1219	
	istry	CRE		0.5		0.5		1.5	
	n chem	BUN		20.5		21.1		18.9	
	and serum	GLU		- 65		82		87	
	Hematology	MCHC		32.7		34.7	3	33.9	
,	He	MCH	, , ,	9.17		7.77	1	22.4	
		WBC		10.7		1		1.5.	
		HGB		12.4		1.7.1	-	13.0	
		HCT	2 2 2	37.9	1 / 5	30.7	107	38.3	
		RBC	20.0	5.73	17.3	2.01	2	5.19.	
		Time	Desertions	Daseline	114.	11111	471	TOIL	

### 3MAY99 Exposure Multisol Oral

Г	Т	T		_		T	_	L	7	
	ت	5   5		5	108		<u> </u>	103	201	101
	K	3.4	3.5	;	4	: '	ر. د.	36	;	3.5
	Z,	145	145	2	147		/ + 1	145		146
	SGPT	61	23		27	C.	7+	09		56
	SGOT									
	CPK	268	959		488	225	623	110		186
nistry	CRE	1.6	1.7		1.5	<b>V</b>		1.6		1.5
serum chemistry	BUN	16.9	15.3		18.9	125	5.51	16.7		17.3
E	1	19	40		82	88	99	911	000	86
Hematology a	MCHC	33.3	34.2		32.5	315	5.1.5	33.9	0 00	33.8
H	MCH	22.1	22.6		21.4	20.6	2.0	22.4	200	77.7
	WBC	9.93	17.5		13.9	10.7		0.11	101	7.7
	HGB	13.4	14.5		13./	13.2		14.5	77	7.41
	HCT	40.1	42.3	707	47.3	41.8	1	47.7	127	47.
	RBC	6.07	6.41	67.7	24.0	6:36		0.47	637	0.37
	Time	Base	+1hr	1642	TOIL	+24h	100	u7/+	490+	1201

Methemoglobin Sample Table 03SEP98 WR242511 3.5 mg/kg IV

		QHW.	10.1	6.7	0.3	7.3	5.4	7.6	0.0		7.6	1	5.0		4.6		3.5		4.6		8.8		8.7	
AN ANGELL CAN	200	OSOU	0.'	70	0.0	0.7	0.7	0.7	0.7	o c	0.0	o o	0.8		1.0		1.0		1.0	9	0.8		0.7	
OSM3 2 (no mint			C.O.	-	0.5	0.0	0.0	000	2:0	0	0.0	C	0.7	-	1.0		0.0	c c	0.0		-0.1	000	0.0	
Č		975	0.10	36.3		30.1	30.2	35.0		8 63	0.70	20.7	30.7	27.0	21.3	0.00	7.07	730	23.0	50.4	50.4	48.0	10.7	
		13.3		12.5		12.8	12.8	13.5		12.5	City	110	11.7	110	111.7	7 ()	12.4	17.0	12.0	3 61	14.0	12.0	0.21	
	Ozet	0 01	6 01	6.4	6.4	5.4	5.3	9.9	8.9	9.1	0 1	4.0	3.2	4.1	1.1	0.6	3.7	3.7	4.5	8.7	× ×	2.0	7.5	3
rint)	MHP	6.0	9.0	0.6	9.0	8.0	6.0	9.0	0.7	1.1	10	0.1	80	6.0	10	1:0		0.0	8.0	8.0	60	0.1	1.0	
OSM3 1(Print)	HPCO	-0.8	-0.7	-0.2	-0.3	-0.2	-0.2	-0.3	-0.4	-0.7	9.0-	-0.2	0.0	-0.1	-03	70-	-03	-0.4	-0.3	-0.6	-0.7	9.0-	-0.7	
	H <sub>6</sub> O <sub>2</sub>	55.0	61.1	37.4	37.0	31.2	30.7	36.5	36.6	53.6	53.8	30.6	20.2	24.7	28.9	23.0	22.4	26.7	26.0	50.6	52.4	49.5	54.8	
1	E	13.1	12.8	12.4	12.4	12.4	12.5	13.1	13.3	12.2	12.2	11.6	11.4	11.9	11.4	1.8	11.9	12.5	12.5	12.4	12.1	12.0	9.8	
Sam.	<b>#</b>	1840	1841	1846	1847	1848	1849	1850	1851	9581	1857	1862	1863	1868	1869	1874	1875	1880	1881	1887	1889	1890	1881	
Time	from inj	Base		+1h		49+		+24h		+48h		+72h		496+		+120h		+144h		+168h		+198		
Time		03SEP98					0.400	04SEP98		05SEP98		06SEP98		07SEP98		08SEP98		09SEP98		10SEP98		11SEP98		,

24SEP98 Exposure Multisol IV Methemoglobin Sample Table

Time Tin	Time Sam.		104.8	\$ 2.11	OSM3 1(P	(Print)			Ö	OSM3 2 (no print	(HII)	
<u>#</u>	#   juj un		THE	HbO <sub>2</sub>	Hbco	MHb	Oct	THP		HPCO	S .	200
24SEP98	Pre 1901	╁╌	1	3.5	-0.6	0.5	7.5	12.8	41.9	-0.1	90	7.5
	190	1900 12.4		3.5	-0.5	9.0	7.5					0:,
+	+1hr 190	_		6.0	-0.5	6.0	8.9	12.4	39.5	0.0	90	8 9
	1903	03 12.2		9.0	-0.4	0.7	86.9	12.3	40.1	0.1	0.0	6.0
	19	1904 12.1	-	0.2	-0.5	6.0	8.9					6
	+6h 1905	05 12.5		35.5	-0.3	8.0	6.2	12.7	33.6	0 1	0.4	6.5
	19	1906 12.5		4.9	-0.4	0.7	6.1					

# Methemoglobin Sample Table 3MAY99 Exposure Multisol Oral

	-,	_		-,-	<del>-</del> -	_	<b>-</b> -		<del></del>	<del></del> -						
	Osct	8 1 1	11.9	7.8	97	8 -	7.1	11.7	12.1	0.8	10.4	16.2	12.8	8.5	8 5	
	MHb	0.7	90	9.0	0.4	0.7	0.5	9.0	0.6	0.0	0.5	0.1	9.0	0.5	9.0	
13 B	HPCO	60-	6.0-	9.0-	90-	-0.6	-0.5	-0.7	-0.7	-0.7	-0.7	-	-0.9	9.0-	-0.7	
OSM3 B	HbO,	65.8	63.5	40.9	38.8	41.8	37.2	58.6	6.29	50.6	54.4	92.6	66.7	45.2	45.3	
	THB	12.9	13.5	13.8	14.0	13.9	13.8	13.7	13.8	13.9	13.8	12.6	13.8	13.6	13.5	
	Sample	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	
4,	Ozct	11.7	12.0	7.5	7.6	7.9	7.1	10.8	12.1	9.0	9.6	12.8		8.9	8.9	
	MHb	0.5	0.5	0.5	0.4	0.7	9.0	0.7	9.0	9.0	0.5	0.4		0.5	9.0	
OSM3 A	HPCO	-0.2	-0.2	0.0	0.1	-0.1	0.0	-0.1	-0.2	-0.2	-0.1	-0.2		-0.2	-0.2	
	HbO <sub>2</sub>	64.1	63.8	39.2	38.8	41.4	37.5	56.8	64.1	46.8	49.7	67.2		48.4	47.9	
	THB	13.1	13.5	13.8	14.0	13.8	13.7	13.7	13.6	13.8	13.9	13.7		123.3	13.3	
Sam.	±	5546	5547	5548	5549	5550	5551	5552	5553	5554	5555	5556		5557	5558	
Time from in	fur more	Base		+1hr		+6hr		+24hr		+48hr		+72hr		+96hr		
Time	•	3MAY99						4MAY99		5MAY99		6MAY99		7MAY99		_

1SEP98 Exposure 3.5 mg/kg WR 242511 IV

	_				_	_	7	_	_		,		_		,		
			5	<u>ت</u>	107	2		<u> </u>	100	2 2	3	104	10	10	103	507	_
			14	11	UV	?	4.3	C. <del>+</del>	2	?	2 0	7.7	,	J. V.	9	7.7	
			ž	110	153	,	151	171	151	1.24	151		151	1,74	160	201	
			TdDS	100	S	1	77	?	75	3	20	2	53	3	50	5	
			LOUS	200	<u>-</u>		177	•	2	5	71	2	13	7	517	2	
			CPK		53		213	717	343	710	37	5	63	S	75	3	
	nistry		CRE		?		9	7.0	1 5		1 3	3:	17		1 7	•	
•	m chen		BSN		14.3				2		<u>-</u>	?	12.3		11.2		
-	and serum chemistry		OTO	1	န	ļ	- - -		62	֓֞֜֜֜֜֜֜֜֜֜֜֜֓֓֓֓֜֜֜֜֜֓֓֓֓֜֜֜֜֜֓֓֓֓֓֜֜֜֜֜֡֓֓֓֡֓֜֜֡֓֓֡֓֜֡֡֡֓֜֡֓֡֡֓֜֡֡֓֡֡֡֡֡֡	73		79		35		
	Hematology a		MCHC	22,00	23.0	000	52.9		35.5		34.7		34.2		33.1		
11	He		MCH	212	C+.7	0,50	73.9	-	25.5		24.7		24.8		7.47		
		20/11	×هر	200	1.0	70 6	00./		C:01	200	17.6		7.57	90.0	9.08		
		1100	uCB	17.1	1.7.	15.0	13.3	1	14.	-	7.4		8.4	1 21	13.4		
		TOI	IIC!	41	,	766	2.0	7 . 7	41.4	13.0	43.0		43.4	3 71	40.5		
		שפע	NDC.	7.04	:	7	1.0	21. 3	5.75	603	0.03	90	5.78	76 7	0.30		
		L	711117	Rase		+24b	111.7	7077	1101	100	117/	1/01	+1001	4100k	17771		

7JAN98 Exposure Telazol Only MHb

Γ	_	T	_	T,	- 7		_
		٦	_		711		_
		7	4	,	2.0	-	
		Ž	7	165	25	L	
		CCPT	5	13	£		
		COL	,	CIN	3		
		CPK	-	CIN	ZVI		
mistry		CRE		1.5	7:5		,
m che		BUN		156	2.2.1		
y and seru		GLU		47			
ematology	3	MCHC		34.7			
H		MCH		25.2			
		×BC		7.24			
	1	HGB		14.0			
	1	HCI		47.0			
	Car	RBC.	900	0.78			
	Time	1 11115	67.00	00:40			

· 13JAN99 Exposure WR242511 7.0 mg/kg IV SLOW (60 minutes)

	_	Č	ے ح	911	115	CI	117	9		106	201	103	S	10,		3	103		100
		1	4	0.9	7.3		4.6	6.2	ر. د.ن	2.2		2.7	;	7		3.0	2 6	5.5	3.8
		N.	ואמ	051	1/10		150	110	0+1	152	701	151	151	145	201	701	147	+	152
		CCDT	1 100	25	24		73	30	,	50	2	42	7	57	03	3	30	77	46
		CGOT	3																
		CPK	4	290	340	17.0	4/2	5838	2000	960		225	200	638	223	777	86	3	65
	listry	CRF		 8:	2.1		7.	6	ì	9.1				×:	1,6	7.0	1 6	2	9.1
-	m chen	RIN			15.7			19.2	ı		1	8.7	,		110			-1	7.8
	and seru	GEU		32	44	55	CC	182		<b>%</b>	,	911	100	2	102		92	000	100
201040	ricinatology and serum chemistry	MCHC	200	37.7	34.1	34.1	27.1	34.3		34.4	000	33.9	22.0	07.0	32.4		31.2		31.9
'n	TI	MCH	22.2	77.77	24.8	24.8	2	24.6	0,10	24.8	1 30	7.67	247	7.1.7	23.7		57.9	22.0	7.67
		WBC	1 52	4.33	4.17	4.01		12.7	2/1	(0./	670	20.6	77 8		7.7	200	8.07	120	12.0
		HGB	- 1		12.4	12.3		15.2	1 7 1	14.1	12.6	0.01	13.8	2	13.8		13.0	12.7	13.7
		HCT	35.1	1,7,1	36.3	36.1		44.3	717	41.0	70.2	40.7	410		42.4	917	41.0	13.1	1.01
		RBC	4 87		4.98	4.97	300	0.13	07 5	2.02	CV 5	3:12	5.61		5.81	11.4	3.71	5 70	
		Time	Pre		Omm Omm	- H	1	uo	244	7.11.	48h	1101	144h		168h	1001	11761	216h	TIO I

Methemoglobin Sample Table 1SEP98 Exposure 3.5 mg/kg WR 242511 IV

	MITH	MITE 8.3	6:0	19		6.0	8.7	2	1 %	5	0 8	6	10.3	10.3	0.8	0.0	7 1	7.1	0.8	0:0	3.4	+:0	
9	HECO	0.3	6.5	0.5		5.0	6.0		0.7		8.0	2	7.0		90	9:0	90	2.0	0.7	3	3.0		
OSM3 2 (no print)	HPO.	0.0	2	0 3		0.3	-0.2		-0.2		-01	;	10-	1.0	10		0.0	7:0	-0.2	1	0.0	7:5	
SO	THH	39.68		29.1		33.1	38.1		41.0		45.2		\$2.8		404		10.4		40.6		16.0		
		15.1		15.0		14.9	15.5		14.2		14.2		14.1		14.2		14.4		14.2		15.1		
	O2ct	8.3	8.3	5.4	7.0	6.1	8.1	9.3	8.0	7.9	9.1	8.6	10.8	9.7	7.3	7.8	2.0	2.2	8.2	8.4	3.5	3.7	4.0
int)	MHb	9.0	0.5	0.4	9.0	8.0	6.0	6.0	8.0	0.7	1.0	1.0	6.0	Ξ	0.7	9.0	0.7	0.7	0.7	0.7	0.3	9.0	9.0
OSM3 1(Print)	HbC0	-0.5	-0.5	-0.2	-0.4	-0.2	-0.5	9.0-	-0.4	-0.3	-0.5	-0.5	-0.7	-0.8	-0.2	-0.3	-0.2	-0.1	9.0-	-0.5	-0.2	-0.4	-0.3
	HbO <sub>2</sub>	40.0	39.7	26.6	34.1	30.8	38.1	44.5	41.7	40.7	46.6	44.7	55.1	57.4	37.7	41.5	8.6	11.2	42.5	44.3	16.7	17.9	19.7
	THB	15.0	15.1	14.7	14.7	14.3	15.3	15.1	13.8	14.0	14.1	13.8	14.1	12.2	14.0	13.5	14.5	13.9	13.8	13.7	14.9	14.8	14.7
Sam.	**	1824	1825	1828	1829	1832	9881	1837	1842	1843	1852	1853	1858	1859	1864	1865	1870	1871	1876	1877	1882	1883	1884
Time	from inj	Base		+1h		+6h	+24h		+48h		+72h		496+		+120h		+144h		+168h		+192h		
Date		01SEP98					02SEP98		03SEP98		04SEP98		05SEP98		06SEP98	•	07SEP98		08SEP98		09SEP98		

Methemoglobin Sample Table 7JAN99 Telazol only

		100	220	12.6	0.01	0 7	0.4	10.6	0.0	6 01	
	t)	MUK	TATELLO	0.0	7:0	0.3	5:5	7 0		0.4	
	OSM3 2 (no print)	HPCO		0 1		0.0	0.0			0.1	
	SO		7001	70.1		71.2		56.3		57.1	
		THP	2:::	14.0		14.1		13.5		13.7	
		Oct	2-7-	13.4		13.8		10.5		10.7	
	nt)	MHb		0.5		0.5		0.4		0.4	
- 1 *	USM3 I(Print	HPCO	,	-0.0		-C.O-	,,,	-0.4		-0.4	
		HbO <sub>2</sub>	0.00	/0.3	0 17	0.1/	0 73	7.00	0 2 2	57.9	
		THb		13./	12.0	13.0	101	13.4	12.2	13.3	
800	Salli.	#	10.43	1943	1011	1 744	1015	1743	1016	1240	
Time	7	тош ш	Tel 110	161 +10111			TolalSm	101 101	_		
Time	Allin T		08.40	04.00			08.45	Cr.no	_		

Methemoglobin Sample Table 13JAN98 Exposure WR242511 7.0 mg/kg IV SLOW (60 minutes)

\*

	174		15.7		16.9		10.5		96		2.1		8.2	1	3.2	<u> </u>	57	7.0	4.5	:	6.9		99	2	2.7	3.3
		-						_	-	+	-		  -	-	-	+			7	+			+	-	2	3
m) (iii	0.4		0.4	5	0.5		9.0		0.5		0.4		0.5		90		0.4	9.0	0.7		90		0.4		0.4	0.5
OSM3 2 (no print)	-0.1		0.2		0.3		0.4		-0.1		0.3		0.1		0.1		0.1	-0.1	0.1		0.1		0.1		0.3	0.2
NEO. OS	96.5		95.1		93.7		50.2		49.5		27.0		42.0		16.5		28.9	35.0	23.6		34.8		34.5		13.4	16.5
THB	13.0		12.6		13.0		15.0		13.9		13.7		14.1		14.1		14.3	14.4	13.8		14.2		13.8		14.5	14.4
ð	17.1	17.5	16.7	16.5	16.7	16.8	10.4	10.7	9.3	9.4	5.3	5.2	8.3	8.4	3.4	3.5	5.6	6.3	4.8	7.2	7.3	11.3	9.9	7.0	2.7	3.4
int)	0.3	0.5	0.5	0.5	0.7	0.5	0.5	9.0	9.0	9.0	0.7	9.0	0.5	0.7	0.5	0.7	0.7	8.0	9.0	9.0	0.4	9.0	9.0	9.0	0.5	9.0
OSM3 1(Print) HbCO	-0.7	8.0-	9.0-	-0.7	-0.6	-0.5	-0.1	-0.2	9.0-	-0.6	-0.4	-0.4	-0.4	9.0-	-0.3	-0.4	-0.7	-0.7	-0.4	-0.5	-0.4	-0.7	-0.5	-0.5	-0.3	-0.3
HbO2	97.1	9.96	95.2	95.2	94.6	95.2	51.6	52.4	50.3	50	28.3	27.7	43.4	43.3	17.7	18.1	29.0	32.7	24.7	38.2	37.6	60.2	35.1	37.3	13.4	17.3
QHI.	12.7	13.0	12.6	12.5	12.7	12.7	14.5	14.7	13.3	13.5	13.4	13.5	13.8	13.9	14.0	13.8	13.8	13.9	13.5	13.5	13.9	13.5	13.6	13.5	14.3	14.1
Sam. #	1947	1948	1949	1950	1951	1952	1953	1954	1955	1956	1957	1958	1959	1960	1961	1962	1963	1964	1965	1966	1961	1968	1969	1970	1971	1972
Time from inj	0		+5min		+1hr		+6hr		+24h		+48h		+72h		496+		+120h		+144h		+168h		+192h		+216h	
401304,727	13JAN99								14JAN99		15JAN99		16JAN99	-	17JAN99		18JAN99		19JAN99		20JAN99		21JAN99		22JAN99	

### **JOE RHJW0 Male Rhesus**

1SEP98 Exposure WR242511 3.5 mg/kg IV

г		_	_				Т		T	_	_	_		_	_
		2	3	3	100	3	100	3	106	3	29	3	104		
		2	4	3.4	0	0.0	26	0.0	20	2.7	25		3.5		
		Š	1	153	152	5	151	17	141	171	6		151		
		LdUS			1/8	5	78	5	20	3	52		200		
		TODS		- /+	100	100	58		75	;	52	1	39		
		CPK	22		4024	1	201		996		19	2000	1700		
nistry		CRE	,	·-	91		9		5		5.1	0	0.1		
m chen		BCN	10.5		8.4		13.3		11.5		×:-	100	10.0		
ind seru		OTO —	80	?	85		73		9/	9,	98	82	70		
Hematology and serum chemistry	Ď	MCHC	34.7	21.6	32.7	0,0	36.2	0.00	33.8	340	24.0	34.7	34.7		
Hei		MCH	245	2	23.4	0 30	6.07	0,0	7.67	3 1/6	24.7	24.5			
	200	×BC	17.5		19.3	-	14.0	100	13./	127	13./	15.0			
	1	HOB	17.7		13.4	2.5	7.0	120	13.0	13.1	1.01	13.6			
	11711	HCI	51.7		41.0	207	70.1	20 4	30.4	37.7		39.1			
	200	NO.	7.21	1	5.74	5.41	3.41	5 27	15.0	2,36		5.55			
	L	THIE	Base		+74n	+48h	101	+72	117	+168h		+192h			

29SEP - 10CT98 Exposure WR 242511 7.0 mg/kg IV (Died)

	_	_	ī		1	_	_	_	_
			5	<u>ت</u>		114	701	174	
			1	4	,,	0.0	3.0	٧.٥	
			N.	אַ	150	20	140	147	
			CCDT	5	30	3	27	<u>`</u>	74
			COL		7-1	-	137	-	68
			CPK		07	2	75	ر ۲	1690
	mistry		CRE		91		17	:	7
	m chen		BEE	. ]	10.2		10.7		10.3
	and seru		075		77		94		
	Hematology and serum chemi		MCHC		47.7		34.0		32.8
	He	1000	MCH		2		24.2	2,0	23.5
		200	N P P		77.1		19.7	,	7.17
		1101	200	2	14.9		14.8	- 7	14.3
		TUI	1	213	51.5	43.7	43./	A 2 K	43.3
	•	Jaa	7	00 F	4.70	21.7	0.13	203	
_		Time	2	Dage	Dasc	==		476	711.7

Methemoglobin Sample Table

EST				_	_													-					<del></del> 1
	MHb	8.0		10.0		9.0		8.5		0.9		6.4		4.5		3.6		5.8	7.1		8.5		:
<b>(</b>	HPCO	0.4		0.5		9.0		8.0		8.0		8.0		9.0		0.4		0.7	9.0		0.5		
OSM3 2 (no print)	HbO <sub>2</sub>	0.1		0.1		0.3		-0.2		-0.1		0.0		0.2		0.4		0.1	0.1		0.0		
ISO	THP	39.1		54.3		47.7		45.7		31.5		36.0		23.2		20.3		30.8	38.9		45.7		
		14.7		13.3		13.6		13.4		13.7		12.8		13.8		12.6		13.5	13.1		13.4		
	O2ct	7.8	8.1	10.0	10.3	9.8	9.3	8.5	9.8	0.9	5.8	6.3	6.7	4.6	4.5	3.7	4.2	5.3	6.9	7.4	8.5	9.3	
(a	MHb	9.0	7.0	0.7	9.0	9.0	0.7	1.1	1.0	6.0	6.0	1.1	1.1	1.0	8.0	9.0	0.7	8.0	9.0	9.0	9.0	9.0	
OSM3 1(Print)	HPCO	-0.5	-0.5	-0.4	-0.4	-0.1	-0.2	9.0-	9.0-	-0.3	-0.3	-0.4	9.0-	-0.5	-0.4	-0.1	-0.1	-0.4	-0.2	-0.3	-0.5	-0.5	
	Hb0,	39.0	40.1	55.1	56.7	46.4	49.9	46.1	47.1	32.7	31.5	35.7	38.2	24.2	24.0	20.9	25.8	29.3	38.8	41.4	46.2	52.0	
	THB	14.4	14.5	13.0	13.1	13.4	13.4	13.2	13.1	13.3	13.3	12.6	12.6	13.7	13.5	12.6	11.7	12.9	12.8	12.8	13.2	12.8	
Sam.	#	1826	1827	1830	1831	1834	1835	1838	1839	1844	1845	1854	1855	1860	1861	1866	1867	1873	1878	1879	1885	1886	
Time	from inj	Base		+1h		49+		+24h		+48h		+72h		496+		+120h		+144h	+168h		+192h		
Date		01SEP98						02SEP98		03SEP98		04SEP98		05SEP98		06SEP98		07SEP98	08SEP98		09SEP98		

### **JOE RHJW0 Male Rhesus**

29SEP - 10CT98 Exposure WR 242511 7.0 mg/kg IV (Died)

Methemoglobin Sample Table

HbCO         MHb         O2ct         THb         HbO2         HbCO         MHb         O2ct           -0.5         0.5         11.1         14.8         54.5         0.1         0.5         11.2           -0.6         0.6         11.2         14.8         59.7         0.2         0.7         12.3           -0.5         0.7         12.1         14.8         59.7         0.2         0.7         12.3           0.2         1.0         2.9         14.5         14.8         0.8         0.6         3.0           0.2         1.0         3.0         3.0         3.0         3.0         3.0         3.0           -0.4         0.8         10.3         14.1         52.7         0.2         0.5         10.3	Time Sam.	Sam.				OSM3 1(Print	rint)			C	SM3 2 (no nr	(H)	
0.5         11.1         14.8         54.5         0.1         0.5           0.6         11.2         14.8         59.7         0.2         0.7           0.7         12.3         14.8         59.7         0.2         0.7           0.6         12.1         14.5         14.8         0.8         0.6           1.0         3.9         14.5         14.8         0.8         0.6           0.8         10.3         14.1         52.7         0.2         0.5	# THB	THB	_	HbO <sub>2</sub>	Г	HPCO		O2ct	THh	HHO.	HECO	Muh	1000
0.6         11.2         59.7         0.2         0.7           0.7         12.3         14.8         59.7         0.2         0.7           0.6         12.1         14.5         14.8         0.8         0.6           1.0         3.0         14.5         14.8         0.8         0.6           0.8         10.3         14.1         52.7         0.2         0.5	Base 1910 14.5 55.0	14.5		55.0		-0.5	0.5	11.1	14.8	54.5	0	0.5	11.2
0.7     12.3     14.8     59.7     0.2     0.7       0.6     12.1     14.5     14.8     0.8     0.6       1.0     3.0     14.1     52.7     0.2     0.5	14.5	14.5		55.4		9.0-	9.0	11.2					7:11
0.6     12.1       1.0     2.9       1.0     3.0       0.8     0.6       0.8     0.6       1.0.3     14.1       52.7     0.2       0.5	14.5	14.5		61.2		-0.5	0.7	12.3	14.8	59.7	0.0	0.7	12.3
1.0     2.9     14.5     14.8     0.8     0.6       1.0     3.0     3.0     0.8     0.6       0.8     10.3     14.1     52.7     0.2     0.5	1915 14.4 60.6	14.4	_	9.09		-0.5	9.0	12.1				3	77
1.0     3.0       0.8     10.3       14.1     52.7       0.5     0.5	14.0	14.0		15.0		0.2	1.0	2.9	14.5	14.8	80	90	3.0
0.8 10.3 14.1 52.7 0.2 0.5	1919 14.3 15.3	14.3	_	15.3		0.2	1.0	3.0					25
	+24h 1922 14.0 53.1	14.0		53.1		-0.4	8.0	10.3	14.1	52.7	0.2	0.5	10.3
					L								

20AUG98 WR242511 3.5 mg/kg IV

	_	_	_	_	_			_	_	_								
				<u>ت</u>		101	•	100	3		901	2	2	21		2	101	
			1	4	ļ	9		17	· ·	,	<b>5</b>		7 2	J.C		٧	;	
			12	ZZ.		2		140	}		149		140	\ \ \ \		4X	,	
			CCDT	2	23	S		43	2		2		43	2		74		
			TCC.	1000	5	3,5		œ		~	2	1	49		7	3		
	<u>``</u>		CPK		44	3	2.0	3.19		2	``	900	907		77	-		
20000			3		7		-	?:		7.		-	7:1	-	_	*		
ישושטי		14.14	NO9		73.		7 7	7.1.7	000	70.7		-		173	5/1			
7	į	1 2	232	7.0	+	9	×	3	36	3	3	Ş		2	-			
Hematology an		MUHU	21777	277	7:	7.70	7.4.4		,,,		26.0	37.7		36.3				
He		T U		75.0	2.5	26.7	47.64		7 7	-	26.2	7.0.7	1	9.97			_	
		     	1	6.47		22	;	5	8:1		200	3	6/3	7.0.				
	200	HCB	3	7.7		_		150	2.0					1.7.1				
	101	וים	27.0	2.7	,	33.4		45.0	2.5	, ,	33.3		333	5.5				
	Dag	2	41.7	÷1.5	12.	4.30		6.17		EV V	4.4/		4.55	3				
	Time	A HILLY			1		1	+96h		1111			+764h					

Methemoglobin Sample Table 20AUG98 WR242511 3.5 mg/kg IV

	02ct	10.8		10.6		6.7	6.4	7.1	7.5	9.2		7.8		8.5		2.0	5.4	6.9		8.8	8.8	5.7	4.6	9.6	9.7
int)	MHb	9.0		0.4		6.0	6.0	2.9	2.8	3.6		2.9		2.3		17	1.6	1.4		1.0	6.0	8.0	0.7	0.7	9.0
OSM3 2 (no print)	HPCO	-0.3		0.0		0.2	0.2	-0.2	-0.1	-0.1		0.0		0.0		0.0	0.0	0.0		-0.2	-0.1	0.2	0.2	-0.2	-0.1
h: . 8	H6O <sub>2</sub>	61.2		60.9		38.3	36.4	45.1	46.8	54.8		44.5		50.4		31.3	33.6	43.3		52.9	52.3	33.8	28.8	60.3	59.7
	OHT	17.7		12.5		12.6	12.7	11.4	11.6	12.1		12.6		12.1		11.5	11.6	11.5		11.9	12.1	12.1	11.5	11.5	11.7
	10.7	10.0	10.5	10.3	10./	0.0	0.7	1.1		9.5	8.9	8.0	8./	8.5	8.6	5.0	5.3	6.9	0.8	8.7	8.9	6.3	4.9	7.6	9.0
liit)	0.00	0.6	0.7	0.7	2	9	2.0	6.7		3.9	0.4	3.3	3.5	7.7	2.3	7.0	2.0	0.1	CI	1.2	5.1	0.0	0.0	0.0	0.7
SOSM3 1(Print)	-0.8	-0.8	-0.7	-0.7	-0.2	-03	50-	6.5	20	-0.0	-0.7	0.0	20.0	70-	0.0	4.0	-0.5	-0.0	90-	207	-0.5	P 0-	2.0-	-0.6	
HbO;	62.0	62.2	62.5	64.1	40.6	38.7	49.3		58.2	54.0	47.0	44.6	512	51.1	317	22.0	35.0	44.3	53.3	54.1	38.3	31.3	60.2	60.5	
THP.	12.4	12.6	12.1	12.0	12.1	12.5	11.3		~	911	12.3	12.6	12.0	12.1	13	7	11.2		11.8	11.8	8.11	11.3	11.6	11.4	
26.00	1776	1777	1780	1781	1783	1784	1785	2ndB	1790	1791	1794	1795	1798	1799	1803	1804	1807	18.8	1811	1812	1815	1818	1820	1821	
Frime from Inj	Pre		+1h		49+		+24h		+48h		+72h		496+		+120h		+144h		+192h		+216h	+240h	+264h		
0.00	20AUG98						21AUG98		22AUG98		23AUG98		24AUG98		25AUG98		26AUG98		28AUG98		29AUG98	30AUG98	31AUG98		

20AUG98 WR242511 3.5 mg/kg IV

_			_	_		_	_				_		
	ξ	<u>.</u>	107	2	300	3	101	200	110	2	5	701	
	1	4	6.2	5	27	٠ ٠	2.0	٥.٧	36	0.0	26	0.0	
	No	ING	131	101	1/10	117	140	147	1/10	117	1/10	0+1	
	CCDT	100	33	3	27	2	20	3	43	2	42	1	
	COT	1000	5	1	8	)	80	3	40	`	45	2	
2	CPK	7			_				208				
hemist	CRE		7.		~	2	1.4		1.2		1.2		
serum chemistry	BIN		23.1		21.7		20.9		19.1		17.3		
pg	GLU		4	1	××		36		- 08		- -		
Hematology a	MCHC		34./	1	34.4		33.3		35.2	,,,,	56.3		
Ħ	MCH	†	0.07	000	7.C7		24.3	,	5.07	1	0.02		
	WBC	647	0.47	200	7/7	5	00:11		0.73	6/3	70.0		
	HGB	130	12.7	3 1 5		2	0.01		- /: [	- 2	17.1		
	$\Box$	T	_	Н		r	45.0	t		22.2	_		
	RBC	VI >	7.1.7	75 1	4.70	617	71.0	4 47	4.47	25 V	4.33		
	rime	7.0	2	-74h	7.11	170	7011	1444	1441	-7KAh	40411		

Methemoglobin Sample Table 20AUG98 WR242511 3.5 mg/kg IV

	1	7	$\overline{}$	7	1	_		$\overline{}$	-	-	-	_		$\overline{}$	-	-	_	<del>~</del>	<del></del>			_		<del></del>	
	02ct	10.8		106	0.01	6.7	6.4	7.1	7.5	6.6	!	7.8	2.	8.5		5.0	5.4	6.0		8 8	×	5.7	46	9.6	0.7
nt)	MHh	9.0		0.4	;	6.0	6.0	2.9	2.8	3.6		2.9		2.3		17	91	4		10	6.0	80	0.7	0.7	90
OSM3 2 (no print)	HPCO	-0.3		0.0		0.2	0.2	-0.2	-0.1	-0.1		0.0	,	0.0		0.0	0.0	0.0		-0.2	-0.1	0.2	0.2	-0.2	10-
SO	HbO,	61.2		6.09		38.3	36.4	45.1	46.8	54.8		44.5		50.4		31.3	33.6	43.3		52.9	52.3	33.8	28.8	60.3	59.7
	THP	12.7		12.5		12.6	12.7	11.4	11.6	12.1		12.6		12.1		11.5	11.6	11.5		11.9	12.1	12.1	11.5	11.5	11.7
	O2ct	10.7	10.9	10.5	10.7	8.9	6.7	7.7		9.5	8.9	8.0	7.8	8.5	8.6	5.0	5.3	6.9	8.9	8.7	8.9	6.3	4.9	7.6	9.6
int)	MHb	9.0	9.0	0.7	0.7	1.0	1.0	2.9		3.9	4.0	3.3	3.3	2.7	2.5	2.0	2.0	1.6	1.5	1.2	1.3	1:0	6.0	6.0	6.0
OSM3 1(Print)	HPCO	-0.8	8.0-	-0.7	-0.7	-0.2	-0.3	-0.5		9.0-	-0.7	9.0-	9.0-	-0.7	9.0-	-0.4	-0.5	9.0-	-0.5	-0.6	-0.7	-0.5	-0.4	-0.7	9.0-
	HbO <sub>2</sub>	62.0	62.2	62.5	64.1	40.6	38.7	49.3		58.2	54.9	47.0	44.6	51.2	51.1	31.7	33.8	44.1	44.3	53.3	54.1	38.3	31.3	60.2	60.5
*	THB	12.4	12.6	12.1	12.0	12.1	12.5	11.3		11.8	11.6	12.3	12.6	12.0	12.1	11.3	11.3	11.2	11.1	11.8	11.8	11.8	11.3	11.6	11.4
Sam.	#	1776	1777	1780	18/1	1783	1784	1785	2ndB	1790	1791	1794	1795	1798	1799	1803	1804	1807	18.8	1811	1812	1815	1818	1820	1821
Time	from Inj	Pre		+1h		+6h		+24h		+48h		+72h		+96h		+120h		+144h		+192h		+216h	+240h	+264h	
Time		20AUG98						21AUG98		22AUG98		23AUG98		24AUG98		25AUG98		26AUG98		28AUG98		29AUG98	30AUG98	31AUG98	

### N:/pccommon/AVMoran/Mhbr/drugblood

## Sheba, RH P3C Female Rhesus P3C Sheba - 13AUG98 WR242511 3.5 mg/kg IV

	_																	
				2	3	5	2				2	4	200	0				
				4	4	,	£.3				C T	,	0	0.0				
				ź	3	147	<u> </u>				2	2	OV.	147				
				Ld:DZ	,	ç	77				-	3	δV	2				
			2000	252		~	3			1	÷	,	47					_
	124	Ţ	Muc	2	ļ	-	·				4		3		-			
	hemic	CITTO	Tab	9	6	×.				-	-		4.					_
	rım c		RINI		371					<u> </u>	2:1	. 00	407		_		-	_
	and serum chemister			2	70	`		-	ļ	ž	3	5	3		_			
	Hematology a	ò	MCHO CHO		33.5	1	77	-				30 68	24.0					
;	Hen		MCH		22.4		23.4					200	2			r	_	
		-	_ אפ א	+	3.03		3.74		_			3.42	!		_			-
		401	900	17.7	7.7		14.0				-	×:-						
		LUH	7	721	13.0	-	0.14				176	70.1						
		RRC		V 7 7	1.1	9	7.77				5 27	5.5						
		Time		PRE		404	100	100F	11071		- tx+	1				_		
_						_				_	_				_		_	

P3C Sheba - 29SEP98 WR242511 7.0 mg/kg IV

					_	;	113		Ţ		2	200	2	1	104				5
				;	<u> </u>		-	-	ļ	2		<	÷		5.7	1			0
				-	g		<u>-</u>	7	5	44X		01	2		14/				7.7
				TUUD	250		=	•	000	001		~	?	S	70	-	43	+	_
				TOUS.	7000	ŀ	9	;	180	201		1.2		83	3	5	70		_
		2	,	CPK	1	90	40		280	2	, , , ,	334		2	200		-	3/6	?
	,			SEE.		_	<del>†</del>		<u> </u>	2	-	\ -		7.	!	7		-	C:
	do min			ROS		. 77	7:-		74.4			7:7	0 00	7.57		7 2			2.1.7
	v and co			275		è	,	-	1/		×	3	70	7	9	ŝ		76	
)	Hematology and serum shamist	Ď	MOUN	JEDIN	34.6	0.4.0		300	7.7	210	34.7		33 8	0.00	22.2	5.5	000	33.0	
	Hei		MCH	-	22.7	_	t	_		H		†	200		200	-	t	-	1
			NA CHA		ух У	3		0.0		70	1.7.				7 07	:	20.0	7.0.7	
			HCB		4		2	7.4.7		14.7	•	,	13.3	100	6.67		13.5	3:5	
		1	] H	1	40.7		120	5.5		7		700	77.4	000	30.0		37.X	2	
			200	20.2	5.7.		7.7	5	5	9.6		00	2.7		14.4	200	2.27		
			11110	Dogo	Dasc		+		777	11+7-		+484		1777	117/		1017±		

Sheba, RH P3C Female Rhesus

Methemoglobin Sample Table 21AUG98 3.5 mg/kg WR242511

-		Ozct																		<u> </u>						
	The state of	0																		4.0	3.0	7.8		8.0	7.1	
573	` 1	MHb																	20	0.0	0.7	0.6		0.8	9.0	5
ONO O Kennas	COIM 2 (no print)	HbCO <sub>2</sub>																	1 0-	-0.1	-0.1	-0.1		-0.2	-0.1	
	5	нво,																	23.6	20.3	52.0	32.0	7 67	47.3	47.7	
The state of the s		ु ०मा																	12.3	12.6	10.8	0.01	1 (1	1.71	11.3	
		10.5	10.0	0.01	9.0	6.7	5.1	7.7	12.1	11.5	13.7	12.2	0.01	12.0	13.4	8.6	5.8	6.9	4.3	4.1	7.0	7.8	7.8	7.1	75	;;
(tii)	Mhh	9.0	9.0	0.0	0.6	0.7	0.6	90	9.0	0.5	9.0	0.7	0.0	600	0.0	0.7	0.0	8.0	0.7	8.0	8.0	8.0	0.7	9.0	0.7	
OSM3 I(Print)	HECO.	90-	-0.7	-0.3	-0.4	-0.3	-0.2	-0.3	-0.6	-0.5	9.0-	-0.7	8.0-	00-	50-	0.0	-0.4	-0.0	-0.4	-0.4	-0.4	-0.5	-0.6	-0.5	-0.6	+
X X	1 HBO,	57.1	57.7	47.8	47.6	48.0	28.6	44.0	67.9	65.7	73.5	73.7	75.5	77.5	32.9	32.0	30.0	39.0	24.7	23.7	47.2	6.48	46.1	44.1	46.6	
	THB	13.3	13.1	12.0	11.9	12.2	12.8	12.6	12.8	12.6	13.1	13.0	12.2	12.4	12.6	12.6	1261	0.21	17.7	12.4	10.6	10.2	12.1	11.6	9.11	
Sami		1750	1751	1752	1753	1754	1755	1756	1757	1758	1759	1760	19/1	1762	1763	1764	1765	1766	00/1	/0/1	0//1	1771	1782	1788	1789	
Time	ful mor	Pre		+1hr			+6hr		+24hr		+48hr		+72hr		+96hr			+120hr	11771	1441	+144UL		+168hr	+192hr		
		I3AUG							14AUG		ISAUG		16AUG		17AUG			18AUG	+	50110	+	$\dashv$		FIAUG +		

## Sheba, RH P3C Female Rhesus

Methemoglobin Sample Table 29SEP98 7.0 mg/kg WR242511

02tt	10.1	3.1	8.0	5.3	5.5	3.0	
int) MHb 0.6	0.8	0.7	9.0	0.8	1:1	0.9	
OSM3 2 (tho print) -0.1	0.0	0.5	0.0	-0.1	0.0	-0.1	
——————————————————————————————————————	49.2	14.6	41.0	29.9	37.6	31.3	
THB /	14.7	15.2	14.1	12.8	10.5	11.2	
7.4 7.4	10.0	3.1	8.0	5.3	5.5	4.8	
int)	0.7	0.3	0.7	0.9	11   1	0.6	
OSM3 1(Print) (HbCO -0.6	-0.5	0.0	-0.5	-0.5	-0.4	-0.5	
38.1 38.9	55.3	16.1	41.7	30.0	39.2 39.5 37.8	32.0 19.0 17.3	
Sam: Sam: 14.0	1912 14.5 1913 14.3 1916 14.3	-	++		1925 10.1 1926 10.4 1927 10.6	1928     10.7       1929     12.5       1930     12.3	
	+1h 19	++	++	++	15 13/+ 196+	+120h 19 +216 19	
71me 29SEP98		30SEP98	010CT08	SCI COLO	03OCT98	040CT98 080CT98	

### Appendix G. Original Necropsy Reports

### U.S. Army Medical Research Institute of Chemical Defense Aberdeen Proving Grounds, MD 21010-5425

uplake

ACCESSION NUMBER:

98-1392

VENDOR:		DATE RECEIVED:		INVESTIGATOR:		TOR:	PROTOCOL NUMBER:	
				R	ockw	ood/Baskin	ICD-Diagnostic	
SPECIES:	BREED	STRAIN:	SE	X:	AGE		ANIMAL I.D.:	
NHP		Rhesus		M			JWO	
DATE OF DEATH:		DATE OF NECRO	PSY:			PROSECTOR:		
	10/01/98					Micheltree		

### HISTORY:

This 10.0 kg male Rhesus monkey had received an IV injection of WR 242511 on two separate occasions. The initial solution was prepared in PEG200. Later, because darkened urine was observed in the animal within 1 hr. post-injection, a different solvent (multisol) was used for the 2nd injection. Again, darkened urine was noted within 1 hr post injection and determined to be hemoglobin. It was noted on 30 Sept 98 that JWO had vomited overnight, and had loose stools. It was also noted that day that he was pale, lethargic, and not eating. The animal was given gatorade and a cover, as the animal was shivering. JWO was found dead in its cage at 0730 on 1 OCT 1998.

### **GROSS FINDINGS:**

The carcass was in good flesh and there were no significant gross lesions.

Clinical pathology revealed no significant findings. Bone marrow examination is pending.

### MICROSCOPIC DIAGNOSIS(ES):

- 1. Lungs: Edema, alveolar, acute, diffuse, severe, with marked fibrinous exudate, fibrin thrombi, and alveolar macrophages that contain an acidophilic globular material.
- 2. Heart, myocardial interstitium: Myocarditis, subacute, multifocal, mild, with focal fibrosis and mild epicardial hemorrhage.
- 3. Liver: Congestion, acute, diffuse, marked.
- 4. Liver, hepatocytes: Vacuolar degeneration, diffuse, severe.
- 5. Stomach: Gastritis, lymphohistiocytic, multifocal moderate.
- 6. Kidney: Congestion, acute, diffuse, moderate, with mild tubular degeneration and rare leukocyte casts.
- 7. Adrenal glands: Congestion, acute, diffuse, moderate.

### COMMENTS:

The combination of clinical signs, pulmonary edema, heart lesions, and multiorgan congestion indicates that this animal died of severe cardiopulmonary dysfunction

U.S. Army Medical Research Institute of Chemical Defense Aberdeen Proving Grounds, MD 21010-5425 ACCESSION NUMBER:

98-1392

(continued)

(hypotensive shock leading to acute congestive heart failure). The pulmonary thrombosis and hemoglobinuria suggests a hematologic disorder as the inciting cause. Differential diagnoses in this case would include direct toxic or oxidative destruction of red blood cells (intravascular hemolysis), and possibly a coagulation syndrome. The acute nature of the condition negated accurate hematologic assessment. Vacuolar degeneration of hepatocytes is commonly seen in other species due to an increase in exogenous or endogenous corticosteroids; however, some form of toxic effect on the liver cannot be ruled out. The lesions in the kidney were minimal, but may also suggest a toxicity. The cause of the gastritis was not evident histologically.

REPORTED BY:

Crystal M. Briscoe, MAJ, VC

Veterinary Pathologist Diplomate, ACVP

Comparative Pathology Branch

DATE: 10/22/98

U.S. Army Medical Research Institute of Chemical Defense Aberdeen Proving Grounds, MD 21010-5425 DATE: 04/27/99

ACCESSION NUMBER:

99-391

Vendor:	Da	te received:	received: Investigators:  Dr Rockwood			F	Protocol number:	-	
Species: NHP	Breed	/Strain: us	S	ex:	l	Age:		Animal ID: 6VY	
Date of Death: 25 April 1999		Date of Necro				Pr	osect MA	tor: J Duniho	

HISTORY: Deteriorating health since 23 April 1999 with episodes of vomiting and labored breathing. Treated with intravenous fluids. Blood and coagulated blood noted in oral cavity at death.

GROSS FINDINGS:

1. General: Tattoo on inner left thigh labeled as "6VY". Superficial abrasion with 2 cm scab surrounded by hyperemia on left inquinal/abdominal area.

Presented in good body condition with ample subcutaneous and cavitary fat. Stomach is filled with partially digested granular material. Intestines contain soft, brown digested material, and colon contains formed fecal pellets. Left upper canine fractured. Bilateral buccal laceration on upper and lower lips at the level of canine teeth.

2. Subcutis: Multifocal subcutaneous ecchymoses and hemorrhages ranging from 0.5 to 4 cm on the back extending from the scapular to the lumbar area.

3. Thoracic cavity and heart: Multifocal hemorrhages on epicardium and thoracic wall ranging from 2mm to 2cm in diameter. Superficial subendocardial hemorrhage on interventricular septum in left ventricle 3 cm in diameter.

4. Lungs: Diffuse congestion.

5. Larynx and trachea: Small amounts of regurgitated, partially digested food particles in larynx, and small amounts of brown food particles admixed with mucus.

6. Liver: Diffuse centrilobular white discoloration with superficial, serosal up to 1 cm white nodules.

7. Colon: Multifocal colonic mesenteric nodules/saccules measuring up to 0.5 cm.

MICROSCOPIC DIAGNOSIS(ES): Histopathologic report to follow.

COMMENTS: The blood in the oral cavity noted at death is most likely the result of self-inflicted lip lacerations caused by teeth trauma. The cause of the subcutaneous, thoracic and cardiac hemorrhages cannot be determined frrom the gross necropsy examination. The presence of food particles in the larynx and trachea indicate regurgitation followed by aspiration into the respiratory tract. The exact nature of the liver changes will be determined histologically The cause of death is not apparent from the gross necropsy examination.

STEVEN M DUNIHO MAJ, VC

Steventher

VETERINARY PATHOLOGIST

USAMRICD FORM 11 1 JUNE 95 (revised)

U.S. Army Medical Research Institute of Chemical Defense Aberdeen Proving Grounds, MD 21010-5425

11May99		
ACCESSION NUMBER	:	
99-0391		

VENDOR:	DATE RECEIVED:		INVESTIGATOR:		PROTOCOL NUMBER:	
+			I	Or Rockwood	Diagnostic	
SPECIES:	BREED/STRAIN:	SEX	<b>(</b> :	AGE:	ANIMAL I.D.:	
NHP	Rhesus monkey	1	M		6VY	
DATE OF DEATH:	DATE OF NECRO	PSY:		PROSECTOR:		
04/25/99	04/26/99				MAJ Duniho	

### HISTORY:

See previous pathology report dated 04/27/99

### **GROSS FINDINGS:**

See previous pathology report dated 04/27/99

### MICROSCOPIC DIAGNOSIS(ES):

- 1. Liver, hepatocytes: Degeneration and necrosis, submassive, acute, diffuse, with severe congestion.
- 2. Kidney: Tubular degeneration and necrosis, diffuse, moderate to severe, with multifocal cellular, granular and hemoglobin casts, and tubular and glomerular protein.

3. Adrenal gland, zona reticularis: Necrosis, acute, diffuse.

4. Heart: Hemorrhage, acute, subendocardial and myocardial, multifocal, mild, with myocardial degeneration.

5. Spleen: Congestion, difuse, moderate.

- 6. Esophagus, periesophageal fibroadipose tissue: Hemorrhage, acute, focally extensive, moderate.
- 7. Pancreas: Hemorrhage, acute, periductular, focally extensive, mild.

8. Meninges: Hemorrhage, acute, multifocal, mild.

9. Pericardium: Hemorrhage, acute, multifocal, mild with fibrin thrombi.

10. Thymus: Hemorrhage, acute, multifocal, moderate.

- 11. Esophagus, skeletal muscle: Myositis, chronic, multifocal, moderate, with myofiber loss and regeneration.
- 12. Skin, inguinal area: Dermatitis, subacute, perivascular, multifocal, mild, with hemorrhage and fibrin microthrombi.

13. Fibroadipose tissue, mesentery: Fat necrosis, nodular, focal.

14. Heart: Myocarditis, lymphoplasmacytic, multifocal, minimal.

15. Lung; trachea; thyroid gland; tonsil; salivary gland; lymph node, inguinal; stomach; small intestine; large intestine; diaphragm; urinary bladder; eyes; testis; pituitary gland; peripheral nerve; brain; and bone marrow: No significant lésions.

U.S. Army Medical Research Institute of Chemical Defense Aberdeen Proving Grounds, MD 21010-5425

IIMAY99
ACCESSION NUMBER :
99-0391
+

(continued)
COMMENTS:

The cause of death in this case is attributed to generalized hepatic and renal failure resulting from diffuse and severe hepatocellular and renal tubular degeneration and necrosis. The hepatic and renal lesions are consistent with acute toxic injury, and are most likely the result of direct toxicity or biotransformation of the orallyadministered experimental drug. However, we cannot completely rule out hypoxia as a contributing cause. The contribution of the heart lesions to the cause of death is probably not significant, but cannot be completely disqualified. The presence of hemorrhage in a variety of organs attests to a generalized coagulation deficiency, which is most likely secondary to compromised liver function. The cause of the acute necrosis of the zona reticularis in the adrenal gland is uncertian, but may also be the result of drug toxicity. This region of the adrenal gland is most sensitive to chemically-induced injury. The cause of the splenic congestion is not evident histologically, but may be related to passive congestion, agonal event, or increased splenic removal of altered erythrocytes. The esophageal lesions are consistent with chronic physical trauma, and may be the result of gavage procedures. The lesions from the skin samples collected from the inguinal region are consistent with the blunt trauma noted to that area clinically and during the post mortem examination. The other lesions are common incidental findings, and clinically insignificant.

The post mortem urinalysis revealed abnormally elevated levels of protein and a positive occult blood test. The elevated protein is consistent with lack of tubular resorption secondary to tubular damage. The positive occult blood test represents either an elevated presence of hemoglobin or myoglobin. In this case, the result is consistent

with intratubular hemoglobin casts observed histologically.

REVIEWED BY:

Steven M. Duniho

MAJ, VC

Comparative Pathology Branch

Cuptul M. Briscoe

Crystal M. Briscoe

MAJ, VC

Chief, Comparative Pathology Branch

DATE:

05/11/99

### Appendix H. Purity Tests

### **Drug Purity**

Mass Spectrometry

Conducted by:

Dr. Ming L. Shih and Mr. John R. Smith

Conducted on:

WR242511 and solvent samples

Dates conducted:

17-19 May 1999

Pyrogen testing

Conducted by:

Celsis Laboratory Group

Conducted on:

WR242511 and solvent samples

Dates conducted:

29-31 October 1998

Other purity tests

Conducted by:

SRI International (San Francisco, CA) via WRAIR

(Mr. Bill Ellis, personal conversation, October 1999)

Conducted on:

WR242511 sample sent from USAMRICD to WRAIR on 1

September 1999

Dates conducted:

~October-November 1999

### Appendix I. Pyrogen Testing Results

CELSIS NJ

### **Celsis Laboratory Group**

October 31, 1998

SUBMITTED TO:

US Army/MRICD

**ASSAY NUMBER:** 

820568

RECEIVED:

10/29/98

TEST MATERIAL:

**PEG 200** 

Lot/ID#: None

METHOD OF ASSAY:

USP 23 <85> Bacterial Endotoxins Test

### **REAGENTS:**

- E. coli endotoxin ACC Lot 74 exp. 2/6/02 1000 EU/mi 1.
- Lysate (pyrotel) ACC lot 598-02-048 exp. 2/17/03 Sensitivity: 0.03 EU/ml 2.
- 3. Positive Control: 0.08 EU/ml
- Water: Biowhittaker LAL Reagent Water Lot 8M0864 exp. 5/11/00 4.

### RESULTS: (Endotoxin Standard)

- (0.024 ng/ml) 0.12 EU/ml (0.012 ng/ml) 0.08 EU/ml
- (0.006 ng/ml) 0.03 EU/ml
- (0.003 ng/ml) 0.0015 EU/ml
- (0.0015 ng/ml) 0.0075 EU/ml

### **Positive Control**

**Negative Control** 

Sample Dilutions	2 lambda spiked	Unspiked
1:10		
1:20	++++	
1:40	++++	
1:80	++++	

CONCLUSION:

The sample contains <0.6 EU/mL active substance.

Work Approved by:

Anthony T. Grilli, M.S. **Director of Microbiology** 

### **Celsis Laboratory Group**

1/323465115

October 31, 1998

SUBMITTED TO:

US Army/MRICD

**ASSAY NUMBER:** 

820569

RECEIVED:

10/29/98

TEST MATERIAL:

Multisol

Lot/ID#: None

**METHOD OF ASSAY:** 

USP 23 <85> Bacterial Endotoxins Test

### **REAGENTS:**

- 1. E. coli endotoxin ACC Lot 74 exp. 2/6/02 1000 EU/ml
- 2. Lysate (pyrotel) ACC lot 598-02-048 exp. 2/17/03 Sensitivity: 0.03 EU/ml
- 3. Positive Control: 0.06 EU/ml
- 4. Water: Biowhittaker LAL Reagent Water Lot 8M0864 exp. 5/11/00

### RESULTS: (Endotoxin Standard)

- (0.024 ng/ml) 0.12 EU/ml +
- (0.012 ng/ml) 0.06 EU/ml ++
- (0.006 ng/ml) 0.03 EU/ml ++
- (0.003 ng/ml) 0.0015 EU/ml -
- (0.0015 ng/ml) 0.0075 EU/ml

Positive Control

++

**Negative Control** 

\_ .

Sample Dilutions	2 lambda spiked	Unspiked
Undil.	• • • •	
1:2	- n - p	
1:4		
1:8		
1:16	++++	• •
1:32	++++	

**CONCLUSION:** 

The sample contains <0.48 EU/mL active substance.

Work Approved by:

Anthony T. Grilli, M.S.

Director of Microbiology

New Jersey Division 165 Fieldcrest Avenue • Edison, New Jersey 08837 • 732 346-5100 • Fax 732 346-5115

Calsis Laboratory Group, a global natwork of contract laboratories represents that this is a coefidential report which may be used when requested by physician and health efficials, but is not to be used in any form of advertising without written permission.



### **DISTRIBUTION LIST**

Addresses C	opies	
DEFENSE TECHNICAL INFORMATION CENTER ATTN DTIC OCP 8725 JOHN J KINGMAN RD STE 0944 FT BELVOIR VA 22060-6218	2	DIRECTOR 1 ARMED FORCES MEDICAL INTELLIGENCE CENTER 1607 PORTER STREET FORT DETRICK MD 21702-5004
COMMANDER US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND ATTN MCMR PLD 504 SCOTT ST FORT DETRICK MD 21702-5012	2	COMMANDER 1 US ARMY INSTITUTE OF DENTAL RESEARCH BUILDING 40 WASHINGTON DC 20307-5300
HQDA OFFICE OF THE SURGEON GENERAL 5109 LEESBURG PIKE SUITE 691 FALLS CHURCH VA 22041-3258	1	COMMANDER 1 US ARMY INSTITUTE OF SURGICAL RESEARCH BUILDING 2653 FORT SAM HOUSTON TX 78234-6200
DIRECTOR WALTER REED ARMY INSTITUTE OF RESEARCH ATTN MCMR UWZ L 503 ROBERT GRANT AVENUE	1	COMMANDER 1 USAMEDD CENTER & SCHOOL ATTN MCCS FC FORT SAM HOUSTON TX 78234-6100
SILVER SPRING MD 20910-7500  COMMANDER US ARMY AEROMEDICAL RESEARCH LABORATORY	1	COMMANDER 1 USAMEDD CENTER & SCHOOL ATTN MCCS FCD FORT SAM HOUSTON TX 78234-6100
ATTN SCIENTIFIC INFORMATION CENTER PO BOX 577 FORT RUCKER AL 36362-5000	<b>a</b>	DIRECTOR  ENVIRONMENTAL AND LIFE SCIENCES  OFFICE OF THE DEPUTY DIRECTOR FOR  RESEARCH AND ENGINEERING
COMMANDER US ARMY MEDICAL RESEARCH INSTITUT OF INFECTIOUS DISEASES	1 E	ROOM 3D129 WASHINGTON DC 20301-2300
1425 PORTER ST FORT DETRICK MD 21702-5011		COMMANDER US ARMY TRAINING AND DOCTRINE COMMAND
COMMANDER US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE	1	ATTN ATMD FORT MONROE VA 23651
ATTN MCMR UE ZS (MS SAFRAN) BUILDING 42 NATICK MA 01760-5007		COMMANDER US ARMY NUCLEAR AND CHEMICAL AGENCY 7500 BACKLICK ROAD BUILDING 2073
COMMANDANT US ARMY CHEMICAL SCHOOL ATTN ATZN CM C	1	SPRINGFIELD VA 22150-3198

US ARMY MEDICAL MATERIEL DEVEOPMENT ACTIVITY	ı	BUILDING RM A217 BOLLING AFB DC 20332	•
ATTN MCMR UMD 622 NEIMAN ST FORT DETRICK MD 21702-5009  EXECUTIVE OFFICER NAVAL MEDICAL RESEARCH INSTITUTE NAVAL MEDICINE COMMAND NATIONAL CAPITAL REGION	1	COMMANDER US ARMY EDGEWOOD CHEMICAL AND BIOLOGICAL CENTER TECNICAL LIBRARY ATTN AMSSB RC I (E3330) E5183 BLACKHAWK ROAD ABERDEEN PROVING GROUND MD 21010-5424	1
BETHESDA MD 20814  DEPARTMENT OF THE NAVY 1  NAVAL POSTGRADUATE SCHOOL  DUDLEY KNOX LIBRARY  411 DYER ROAD		LTC RICHARD R. STOTTS BATTELLE MEMORIAL INSTITUTE JM 3 505 KING AVENUE COLUMBUS OH 43201-2695	1
ROOM 110 MONTEREY CA 93943-5101		COMMANDER US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE	23
USAF ARMSTRONG LABORATORY/CFTO SUSTAINED OPERATIONS BRANCH BROOKS AFB TX 78235-5000	1	3100 RICKETTS POINT ROAD ATTN MCMR UV ZA MCMR UV ZB MCMR UV ZS	
DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH THE NATIONAL LIBRARY OF MEDICINE SERIAL RECORDS SECTION 8600 ROCKVILLE PIKE BETHESDA MD 20894	1	MCMR UV RC (5 copies) MCMR UV R (11 copies) MCMR UV AI W MCMR UV D MCMR UV P MCMR UV C ABERDEEN PROVING GROUND MD 21010-5425	
STEMSON LIBRARY ACADEMY OF HEALTH SCIENCES BUILDING 2840 RM 106 FORT SAM HOUSTON TX 78234-6100	1	21010-0-20	
US ARMY RESEARCH OFFICE ATTN CHEMICAL AND BIOLOGICAL SCIENCES DIVISION PO BOX 12211 RESEARCH TRIANGLE PARK NC 27709-221	1		